This chapter should be cited as follows: This chapter was last updated:
Wei, J, Glob. libr. women's med.,
(ISSN: 1756-2228) 2009; DOI 10.3843/GLOWM.10230
August 2009

Cervical carcinoma

Pathology of Cervical Carcinoma

Jian-Jun Wei, MD
Associate Professor, Department of Pathology, Northwestern University Feinberg Memorial Hospital, Chicago, Illinois, USA

INTRODUCTION

In the last three decades the epidemiology of cervical cancer has undergone some important changes. In America, it is currently the third most common gynecologic cancer following those of the endometrium and ovary. However, the number of women dead of cervical cancer is exceeded only by that of women dead of ovarian cancer.1 The survival rate following cervical cancer has not improved substantially over the past 25 years.1 Squamous cell carcinoma, which comprised more than 90% of primary cervical cancers before 1960, has been reduced steadily, in large part owing to effective cytologic detection and subsequent eradication of its precursors. In addition, the use of endocervical sampling devices, such as Cytobrush (International Cytobrush, Inc., Hollywood, FL, USA) and Cervex (Rovers BD, Oss, The Netherlands), has enhanced the detection of cervical glandular dysplasia and neoplasms. Consequently, there is a relative increase in cervical adenocarcinoma comprising 13–34% of all cervical cancers.2, 3, 4 Whether the incidence of cervical adenocarcinoma has actually increased remains to be clarified.

In addition to squamous and glandular neoplasms, neuroendocrine, mesenchymal, and metastatic tumors also involve the cervix. New techniques in diagnosis have helped to modify histologic classifications. Specifically, the use of immunohistochemistry in the last decade has improved diagnostic accuracy. This chapter deals primarily with cervical malignancies and precursors of squamous and glandular carcinoma. The emphasis is on proper handling and reporting of surgical specimens, pathologic classification and criteria, and important pathologic parameters, which all have an impact on the prognosis and management of the patient. Finally, investigative findings are described to provide additional insights on the current development.

PROPER HANDLING AND PROCESSING OF CERVICAL SPECIMENS

The accuracy of histologic interpretation and diagnosis is strongly governed by the quality of tissue provided, and proper handling and processing of the specimen. In cervical biopsy specimens, many factors lead to unsatisfactory specimens. Distortion and crush artifacts usually result from the use of dull or small instruments.5 Damage and denudation of the mucosa occur readily even with minor trauma to the cervix. Poor orientation with tangential sections not only precludes accurate interpretation and measurement of stromal invasion, but also contributes to erroneous diagnoses. After the tissue is obtained, the specimen should be placed on a piece of paper towel with the mucosal surface upward and the base of the tissue downward. After the blood and mucus at the base of the tissue become adherent to the paper towel, the specimen and the paper towel are placed in buffered formalin and submitted to the laboratory accompanied by adequate demographic and clinical information.

The single most common cause of an inadequate biopsy specimen is the failure to provide abnormal tissue of sufficient amount and depth. Without the underlying stroma, an invasive neoplasm is likely to be interpreted as in situ cancer. Verrucous squamous carcinoma and papillary, exophytic neoplasms are particularly prone to be underdiagnosed as a benign proliferation, when the specimen contains only the superficial layers. Unless the specimen includes the base of the tumor and its underlying stroma, a correct diagnosis may not be made. In mixed tumors (e.g., adenosquamous carcinoma or carcinosarcoma), an inadequate biopsy specimen may not contain both cellular elements, again resulting in misdiagnosis. Since the most early squamous dysplasia occurs in the columnar and squamous junction, biopsies from either endocervix or ectocervix only are inadequate for pathological evaluation.

For the diagnosis and treatment of cervical intraepithelial neoplasia (CIN), cervical tissue removed by loop electrosurgical excision procedure (LEEP) has become widely accepted. The pathologist usually receives tissue from the anterior lip and the posterior lip, respectively. A third disc-shaped tissue fragment from the base of excision or endocervical margin is received. Diagnostic problems of these specimens are most often caused by a lack of orientation and thermal damage. The specimen should be oriented by a suture or ink to indicate 6 and 12 o'clock. This allows sectioning along the axis of the cervical canal. Without orientation, the specimen may be cut erroneously and the lesion may be missed entirely. Excessive maneuvers by the surgeon or pathologist lead to extensive denudation and loss of the cervical mucosa and the lesion. Prolonged contact between the loop and the tissue results in broad zones of thermal damage, coagulative necrosis, and tissue distortion that preclude an accurate diagnosis of the lesion and the status of excision margins. In one study, 20% of ectocervical margin and 44% of endocervical margin removed by LEEP were unsatisfactory for evaluation.6 With proper surgical technique, orientation of the specimen, and marking of the margins by the surgeon, most LEEP specimens are reported to be adequate for interpretation. The status of excision margins correlates well with the subsequent recurrence of CIN.7

Cervical conization by cold knife is most often performed for large, high-grade CIN and CIN suspected with coexisting invasive carcinoma. If cervical biopsy specimen or endocervical curettage specimen suggests the possibility of severe glandular dysplasia or adenocarcinoma in situ, cervical conization is used to confirm the diagnosis and to exclude coexisting invasive adenocarcinoma. A deep cone is appropriate for young women with adenocarcinoma in situ, who desire to retain fertility.

Cervical conization specimens should be oriented by placing a suture at 12 o'clock, and should be submitted to the laboratory in the fresh state. After opening at 12 o'clock along the cervical canal, the specimen is pinned out on a cork board, immersed in fixative, and subsequently blocked around the clock. This method of sectioning provides vertical cuts through the mucosa and wall allowing for accurate determination of the disease process, and its extent, depth, dimension, and relation to the surgical margins.5 If the specimen is already fixed, it is too rigid to be spread open.

In radical hysterectomy specimens, representative sections should include the most advanced area of tumor to determine the maximal stromal invasion. All surgical margins should be carefully identified and marked with India ink. The parametrium needs special attention, as involvement of this area by the tumor has important clinical implications.

Pelvic lymph nodes should be properly labeled as to their anatomic sites. Benign germinal inclusion cysts (endosalpingiosis) and decidual cells are known to occur in the pelvic wall, peritoneum, and pelvic and paraaortic lymph nodes. Without knowledge of a pregnancy history, decidual cells in lymph nodes and pelvis may be misclassified as metastatic carcinoma cells on frozen sections. Similarly, tissue reactions to prior surgery, radiation, and complications, such as intestinal perforation, can be difficult to separate from malignant tumor, especially on frozen sections. Thus, an accurate pathologic interpretation requires a close collaboration, communication, and understanding between the clinician and the pathologist.

In radically resected uteri, the pathology report should include the following:

  • The local extent of tumor expressed by the depth of stromal invasion in millimeters and percent of cervical wall involvement (alternatively upper third, middle third, deeper third, upper half or deeper half), and the relation to parametrium
  • The presence or absence of lymphatic-vascular space invasion 
  • The status of surgical margins: vaginal, pericervical, and parametrial

When the tumor is deeply invasive, its closeness to the parametrium and parametrial margin should be expressed by measurement in millimeters. Involvement of endometrium should be noted, although its presence does not alter the FIGO stage. All pelvic and paraaortic lymph nodes received should be embedded and carefully studied, sometimes by multiple levels as indicated by the institutional guidelines.

MORPHOGENESIS OF CERVICAL CANCER

The ectocervix is covered by mature squamous mucosa, whereas the endocervix is lined by mucus secreting endocervical epithelium. The latter undergoes squamous metaplasia through reserve cell hyperplasia. In addition, endometrial cells, metaplastic glandular cells (ciliated tubal, serous, and oxyphilic cells), and mesonephric remnants occur in the endocervix. Rare neuroectodermal cells (argyrophilic, neuroendocrine, melanocytic cells) also exist in the normal cervix. These epithelial and neuroectodermal cells are potential progenitors or components of cervical carcinoma. Cervical stromal cells may rarely become neoplastic presenting as a pure mesodermal tumor or mixed with an epithelial neoplasm.

Most cervical squamous carcinomas originate from the metaplastic squamous epithelium located between the original and new squamocolumnar junctions, the transformation zone. Adenocarcinomas occur within the cervical canal, and 25–50% of these contain squamous elements. Undifferentiated carcinoma may contain malignant neuroectodermal cells, squamous cells, and glandular cells.

Clinical and pathologic data support the concept that most invasive carcinomas develop through the stages of intraepithelial neoplasia and microinvasive carcinoma. Although the cause of cervical cancer remains to be determined, human papillomavirus (HPV) DNAs, particularly high-risk types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, and 58, have been identified in squamous, glandular, neuroendocrine, and undifferentiated neoplasms of the cervix by molecular techniques.8 HPV infection is believed to play an important role at least as an initiator of cervical neoplasia.

CLINICAL PRESENTATION AND NATURAL HISTORY OF CERVICAL CANCER

Carcinoma of the cervix may have a variety of clinical presentations. It may be discovered on routine Papanicolaou (Pap) smear in an asymptomatic woman; patients may present with irregular vaginal bleeding; or, in late stages, patients may present with symptoms of a mass lesion or metastatic disease. The cervix with early carcinoma has a poorly circumscribed granular or eroded appearance and bleeds easily on contact. At later stages, nodular, ulcerated lesions or an exophytic mass appears. Endophytic growth occurs in the cervical canal with direct infiltration into the wall causing diffuse enlargement and hardening of the cervix. The mucosal surface may be covered by normal epithelium, and the underlying malignant cells may escape detection by cytologic smear. Some cervical carcinomas are located in the cervical canal and grow endophytically without causing gross abnormality. When the cervix is diffusely enlarged, bulky, and larger than 6 cm in size, it is referred to as a barrel-shaped cervix. This gross appearance can be seen in any tumor type, although it is most commonly associated with adenocarcinoma.

Local extension of cervical carcinoma proceeds in a predictable manner to involve the endometrium superiorly and the upper vagina inferiorly. Parametrial involvement results from extension through the cervical stroma. From the parametrium the tumor may extend laterally to the pelvic sidewall, anteriorly to the bladder base or posteriorly to the rectum. An unusual pattern of local spread is in the form of squamous cell carcinoma in situ into the endometrium, fallopian tubes, and ovaries. Vascular and lymphatic invasion occurs early leading to pelvic lymph nodal metastasis.

International Federation of Gynecologists and Obstetricians (FIGO) updated their clinical staging system in 19959 to utilize the findings of pelvic examination, radiology, and endoscopy. These criteria are summarized in Table 1 with revision in 2009.10

Table 1. Definition of FIGO clinical staging for cervical cancer

Stage

Definition

I

Carcinoma strictly confined to the cervix (extension to the corpus should be disregarded)

 IA

Invasive cancer identified only microscopically; invasion limited to measured stromal invasion with maximum depth of 5 mm and no wider than 7 mm (the depth of invasion should not be more than 5 mm taken from the base of the epithelium, either surface or glandular, from which it originates; vascular space involvement, either venous or lymphatic, should not alter the staging)

  IA1

Measured invasion of stroma no greater than 3 mm in depth and no wider than 7 mm

  IA2

Measured invasion of stroma greater than 3 mm and no greater than 5 mm and no wider than 7 mm

 IB

Clinical lesions confined to the cervix or preclinical lesions greater than stage IA

  IB1

Clinical lesions no greater than 4 cm in size

  IB2

Clinical lesions greater than 4 cm in size

II

The carcinoma extends beyond the cervix but has not extended to the pelvic wall; the carcinoma involves the vagina but not as far as the lower third

 IIA

No obvious parametrial involvement, the cancer may have grown into the upper part of the vagina

  IIA1Tumor size of less than or equal to 4 cm with involvement of less than the upper two-thirds of the vagina
  IIA2Tumor size of more than 4 cm with involvement of less than the upper two-thirds of the vagina

 IIB

Obvious parametrial involvement

  IIB1Unilateral parametrial invasion
  IIB2Bilateral parametrial invasion

III

The carcinoma has extended to the pelvic wall; on rectal examination, there is no cancer-free space between the tumor and the pelvic wall; the tumor involves the lower third of the vagina; all cases with a hydronephrosis or nonfunctioning kidney are included unless they are known to be due to other causes

 IIIA

The cancer has spread to the lower third of the vagina but not to the pelvic wall

 IIIB

The cancer has grown into the pelvic wall. If the tumor has blocked the ureters (a condition called hydronephrosis) it is also a stage IIIB

IV

The carcinoma has extended beyond the true pelvis or has clinically involved the mucosa of the bladder or rectum; a bullous edema as such does not permit a case to be allotted to stage IV

 IVA

Spread of the growth to adjacent organs

 IVB

Spread to distant organs


Adapted from New gynecologic cancer staging: FIGO Cancer Committee. Int J Gynecol Obstet 2009;105:107

CERVICAL SQUAMOUS PRECANCER LESIONS

Cervical squamous precancer lesion (cervical intraepithelial neoplasia, CIN)

Cervical intraepithelial neoplasia (CIN) is a relatively common problem, especially in women of reproductive age. Laboratory surveys from the mid-1990s from the College of American Pathologists suggest that more than 1 million women are diagnosed each year with low-grade cervical intraepithelial lesions, referred to as CIN grade 1 (CIN 1), and that approximately 500,000 are diagnosed with high-grade cervical cancer precursor lesions, referred to as CIN 2-3.11 Squamous carcinogenesis in the cervix has been studied extensively in the past two decades.12 The current biological understanding of the HPV-related spectrum of squamous neoplasia in the cervix is generally divided into two categories: reactive nonneoplastic processes (condyloma or low grade) and precursors of squamous cell carcinoma (a high grade lesion, or CIN 2-3 and carcinoma in situ (CIS)). 

Of the more than 150 HPV types known to exist, only about 30 types of HPV viruses are known to increase the risk of cervical cancer. High risk (carcinogenic) types of HPV include HPV 16, 18, 30, 33, and 45. These, along with another 14 variants, account for approximately 99% of all cervical cancer cases (Table 2).13 About 70% of all cervical cancers are caused by HPV 16 and 18.  Low-risk HPV types, such as HPV 6 and 11, usually result in condyloma and low-grade dysplasia (CIN 1) and the high-risk HPV types, most commonly HPV 16 and 18, usually result in the full range of dysplasias (CIN 2 and CIN 3/CIS).

Table 2.   HPV types and risk of cervical carcinogenesis13

 Most common types 
 6, 11 Condyloma acuminatum, flat condyloma
 16 All grades CIN, squamous cell carcinoma
 18 All grades CIN, adenocarcinoma, squamous cell carcinoma
 Less common types 
 30, 40, 58, 69 All grades CIN
 31, 33, 35, 39, 45, 51, 52, 56 All grades CIN, squamous cell carcinoma

Condylomata 

Condyloma acuminata (Fig. 1A) of the cervix are relatively uncommon in comparison to flat condyloma (Fig. 1B). They are associated with the infection of HPV types 6 and 11 and some other low-risk types. HPV 6 and 11 account for about 95% of genital condylomata. Larger condyloma acuminata can be seen with the naked eye. If left untreated, most condylomata regress (Table 3), although recurrence is common. Condylomata are frequently associated with cervical intraepithelial neoplasia (CIN), quite commonly due to multitype HPV infection (accounting for over 40% of patients), occurring either at the same time or subsequently. Hence a patient with a cervical wart must have continued cytological surveillance. Cytological features of condyloma include large and hyperchromatic nuclei (typically, the nucleus is englarged 3–4 times in affected areas compared to a normal intermediate cell), irregular nuclear membrane, binucleate or even sometimes multinucleate, individual cell keratinization (dyskeratosis), nucleate keratinized cells, and koilocytic change (enlarged cells with perinuclear cytoplasmic clearing; pyknotic nuclei with irregular membranes). Koilocytes are usually found in condyloma and CIN 1 lesions (Fig. 1).

Table 3.   Natural history of CIN: a meta-analysis14

                         

 Regress (%) 

 Persist  (%)  

Progress to CIN3 (%)  

Progress to invasion (%)

HPV

 80

 15

 5

 0

CIN 1

 57

 32

 11

 1

CIN 2

 43

 35

 22

 5

CIN 3

 32

 <56

 -

 >12

 

Fig. 1. Cervical condyloma. (A) Condyloma  acuminatum shows papillomatosis, acanthosis, parakeratosis, and hyperkeratosis. Each papillary frond has a tiny blood vessel at its core. (B) Flat condyloma has koilocytotic atypia, individual cell keratinization (dyskeratosis) and multinucleation. (Hematoxylin-eosin stain, red bar: original magnification.)

 

 

 


Cervical intraepithelial neoplasia (CIN) 

Cervical intraepithelial neoplasia is a precancer lesion and characterized by abnormal cell proliferation of the parabasal cells induced by infection of high risk HPV. High risk subtypes of HPV virus integrate with host DNA, disrupting the E2 region and causing loss of transcriptional control of viral sequences E6 and E7. Overexpression of E6 and E7 accelerates proteolytic degradation of p53, blocks function of p21, and E7 binds the RB gene, eventually displacing sequestered transcription factors. Loss of the retinoblastoma gene product–E2F complex results in overexpression of p16.15 Loss of p53 and RB gene functions, which causes the dysfunction of cell proliferation control, is the key step in the tumorigenesis of cervical dysplasia.

Cervical intraepithelial neoplasia is subjectively classified into mild, moderate, and severe dysplasia. Squamous dysplasia is characterized by abnormal parabasal cell proliferation, loss of polarity, overlapping nuclei, high nuclear and cytoplasmic ratio, increased mitosis, dyskeratosis and apoptosis, and significant nuclear atypia.  

CIN 1 (mild squamous dysplasia, Fig. 2A) is defined by dysplastic squamous cells in the lower third of the epithelium along with HPV changes in the rest of the superficial epithelium. A meta-analysis of HPV types associated with CIN 1 illustrated that HPV-16 was the single most common genotype identified. HPV-16 is found in 26.3% of all HPV-positive CIN 1.12 HPV-31, -51, and -53 were the next most commonly identified HPV types. Each type is identified in 10–12% of CIN 1 lesions. CIN 1 lesions can also be associated with low-risk types of HPV.16 However, HPV-6 or -11 was detected in only 12% of the HPV DNA-positive CIN 1. 

CIN 2 (moderate dysplasia, Fig. 2B) is defined by presence of dysplastic squamous cells in the basal two-thirds of the epithelium; the upper half of the epithelium shows some differentiation and maturation, with, as in CIN 1, nuclear atypia persisting to the surface. Nuclear abnormalities are more marked than in CIN 1, and more nuclei with greater degrees of abnormality are found high in the epithelium. The diagnosis of CIN 2 is the least reproducible form of CIN. It probably represents a mixture of true CIN 1 (approximately one-third of cases) and true CIN 3. 

CIN 3 (severe dysplasia, Fig. 2C) is defined by dysplastic squamous cells marked throughout the whole thickness of the epithelium. Maturation and HPV changes, if present, are confined to the superficial third of the epithelium. Generally, mitotic figures are found at all levels of the epithelium and may be numerous, with many abnormal configurations. The findings in the upper portion of the epithelium include more extensive nuclear changes. Although CIN 2 lesions are more likely to regress during long-term follow-up than are CIN 3 lesions (Table 3), CIN 2 and CIN 3 lesions share a number of biological characteristics usually associated with true cervical cancer precursors.13

In contrast to CIN 1 lesions, almost all CIN 2 and CIN 3 lesions are monoclonal proliferations of cells that show evidence of genetic instability.13 The majority of CIN 2 and CIN 3 lesions are aneuploid and have loss of heterozygosity at nonrandom chromosomal loci that may be associated with neoplastic development.17 CIN 2 and CIN 3 lesions also have much less heterogeneity with respect to associated HPV types than do CIN 1 lesions. The top five high-risk types of HPV (16, 18, 31, 33, and 58) are associated with 75% of high-grade cervical lesions. To provide an added measure of safety, CIN 2 is generally utilized as the threshold for treatment in the United States.


Fig. 2.  Cervical intraepithelial neoplasia (CIN). (A) CIN 1: dysplastic squamous cells in the lower one-third of the epithelium with HPV changes in the rest of the superficial epithelium. (B) CIN 2: dysplastic squamous cells in the basal two-thirds of the epithelium and the upper half of the epithelium shows HPV changes; (C) CIN 3: dysplastic squamous cells marked throughout the full thickness of the epithelium. HPV changes are confined to the superficial layer.

 

 

It is not always easy to distinguish the levels of dysplasia on H/E stained slides. Some ancillary tests may be helpful. Ki-67, a widely used biomarker correlated with proliferation, and its immunohistochemical staining pattern is stable, robust, and contrast rich. The percentage of Ki-67 immunopositive cells is an important diagnostic adjunct for the grading of CIN and its diagnostic import is best understood when expressed numerically as the 90th centile stratification index. Cells are identified equidistant along the basement membrane, and then the location of the uppermost Ki-67 reactive cell is recorded as a percentage of the distance to the mucosal surface (Fig. 3). In evaluating Ki-67 reactive cell clusters as a diagnostic adjunct in distinguishing CIN from normal or benign reactive cervical squamoepithelial lesions, it is important to prevent overdiagnosis, and Ki-67 reactive to tangentially cut parabasal cells, inflammatory cells, and immature metaplasia must be carefully excluded.

p16 (p16INK4), the cyclin-dependent kinase 2A inhibitor, helps distinguish CIN from reactive lesions. Since a retinoblastoma protein (Rb)-dependent negative feedback loop regulates p16 expression, continuous inactivation of Rb by HPV E7 results in increased p16 levels.18 Hence, increased p16 levels may reflect HPV-induced dysplasia with deregulated E7 expression. The value of p16 immunoreactivity in cervical lesions has been evalulated extensively.19 Diffuse and strong immunoreactivity for p16 (Fig. 3) is present in virtually all cervical cancers and high-grade intraepithelial lesions infected by high- and intermediate-risk HPVs. While HPV 6 and HPV 11 related low-grade infected lesions show weak or focal immunoreactivity.

 

Fig. 3. Application of Ki-67 and p16 in evaluating cervical intraepithelial neoplasm. (A) About 70% of squamous cells are immunopositive for Ki-67 involving the full thickness of epithelium in a severe dysplasia (CIN 3). (B) Strong and diffuse immunoreactivity for p16 in a severe dysplasia (CIN 3).

 

 

 

 

SQUAMOUS CARCINOMA AND ITS VARIANTS

Carcinoma in situ and microinvasion

Squamous cell carcinoma in situ (CIS, or Bowen’s disease) is, by definition, a malignancy in nature. It differs from cervical squamous dysplasia in that it has the ability to invade tissue (microinvasion). In the case of no microinvasion, CIS is merely synonymous to CIN 3. However, there are some pathological features that differ between CIS and CIN 3. CIS show prominent nuclear atypia, full thickness of dysplastic squamous cells with no mature squamous cells in superfical surface, hyperkeratosis, frequent atypical mitoses, and increased chronic inflammation at the underlying stroma (Fig. 4).

Fig. 4.  Squamous cell carcinoma in situ (CIS) and microinvasion. (A) CIS with neoplastic cells from base to surface with hyperkeratosis, significant cytological atypia, bristle mitoses, and dyskeratosis. (B) CIS with microinvasion illustrates budding off of malignant cells downward into the underlying stroma with significant lymphocytic infiltrate. (Hematoxylin-eosin stain, yellow bars: original magnification.)

 

 

 

Microinvasion was defined by the tumor being identified only by microscopic examination and invasion to a maximum depth of 5 mm and a maximum width of 7 mm. This criterion is based on the revised staging system for carcinoma of the cervix by FIGO in 1994.20 Table 4 lists the risk of vascular invasion, lymph node metastasis, and 5 year survival rates with different depths of invasion. Less than 5 mm invasion was defined as microinvasion as it has excellent 5 year survival rates of above 95%.

Table 4.  Depth of invasion in stage I SCC20

Depth of invasion (mm)

 Vascular invasion (%)

Positive lymph node (%) 

 5-year survival (%)

 <3

 3

 3

 99

 4–-5

 11

 5

 95

 6–10

 21

 6

 91

 11–15

 65

 31

 72

 >19

 69

 47

 63


Squamous cell carcinoma

Squamous cell carcinoma (SCC) is by far the most common tumor of the cervix. While SCCs accounted for upwards of 90% of primary neoplasms several decades ago, the overall frequency has dropped to about 60–80%, while the incidence of endocervical adenocarcinoma is rising.

In 1958 Wentz and Reagan21 divided cervical squamous carcinomas into three cell types: large cell keratinizing, large cell nonkeratinizing, and small cell. With the advent of electron microscopy and immunohistochemistry, it became apparent that what had been termed small cell carcinoma really represents a heterogeneous group of tumors. These include small cell squamous carcinoma, small cell anaplastic carcinoma, and small cell neuroendocrine carcinoma. Furthermore, a newly proposed classification has expanded the spectrum of neuroendocrine carcinoma to include those poorly differentiated large cell carcinomas demonstrating neuroendocrine differentiation by immunohistochemistry.22

Large cell, nonkeratinizing carcinomas account for two-thirds of cases, and have large cells of similar size and shape. The cytoplasm is moderate in amount, eosinophilic to amphophilic, some having individual cell keratinization with distinct cell borders (Fig. 5). Keratin pearl formation should be absent. Nucleoli are prominent and mitotic figures are common. The invasive edge is often smooth.23

Fig. 5. Squamous cell carcinoma of the cervix, large cell nonkeratinizing type. Malignant squamous cells have abundant eosinophilic cytoplasm, distinct cell borders and individual cell keratinization. The irregular, large nuclei contain multiple nucleoli. (Hematoxylin-eosin stain, red bar: original magnification.)

 

 

 

 

Large keratinizing carcinomas acount for one-sixth of cases, and are characterized by sheets and nests of cells with abundant cytoplasm, large pleomorphic nuclei, and inconspicuous nucleoli. Keratin pearls and intercellular bridges are evident. Mitotic figures are noted occasionally, and the growth pattern is largely infiltrative23 (Fig. 6). This diagnosis can be made even if only one pearl is found. Keratin pearls are circular whorls of squamous epithelium with central nests of acellular keratin. Basaloid squamous cell carcinomas (previously called small cell nonkeratinizing carcinoma) account for the remaing one-sixth of cases, and are characterized by loosely cohesive nests and sheets of small to medium sized cells with hyperchromatic nuclei, scant cytoplasm, and small nucleoli. Keratinization is minimal or absent, and mitotic figures are abundant. The nuclear chromatin is finely to coarsely granular, and small nucleoli are often evident (Fig. 7).24 Crush artifact and nuclear smudging are not prominent. The nuclear cytoplasmic ratio is lower than small cell anaplastic carcinoma. The cell borders are also more distinct. Rare cytoplasmic keratinization also belies the squamous nature of the lesion.24 The nuclei are usually fairly uniform, hyperchromatic, small, and display abundant mitotic activity. Necrosis is frequently observed. Tumors of this type in the cervix have been associated with a particularly poor prognosis and are described below as endocrine tumors.

 

Fig. 6. Squamous cell carcinoma of the cervix, large cell keratinizing type. Malignant squamous cells form irregular nests invading the stroma. In the center of the nest, laminated keratin pearls are present. Individual cells have abundant eosinophilic keratinized cytoplasm. (Hematoxylin-eosin stain, red bar: original magnification.)

 

 

 

 

Fig. 7. Squamous cell carcinoma of the cervix, small cell nonkeratinizing type. The malignant squamous cells have small round-to-oval nuclei, finely granular chromatin, and small nucleoli. Most of the tumor cells contain a small amount of eosinophilic cytoplasm. Mitotic figures are abundant. (Hematoxylin-eosin stain, red bar: original magnification.)

 

 

 

The category of small cell anaplastic carcinoma should be reserved for those cervical tumors that resemble small cell or intermediate cell anaplastic carcinomas of the lung.25, 26, 27, 28, 29 Small cell anaplastic carcinoma is made up of sheets and cords of cells diffusely infiltrating a delicate fibrovascular stroma, simulating lymphoma (Fig. 8). The tumor cells have round, oval to elongated, small to intermediate sized nuclei. The nuclear chromatin ranges from coarsely granular to dark and sometimes smudged (Fig. 8). Nucleoli are inconspicuous and mitotic figures are frequent. The cytoplasm is scant, resulting in nuclear molding and high nuclear cytoplasmic ratios. Necrosis and crush artifacts are common. Desmoplastic reaction of the stroma is minimal or absent.

Fig. 8. Small cell anaplastic carcinoma with diffuse infiltrative pattern made up of sheets of malignant cells. The crush artifact with smudged nuclei is characteristic. The small nuclei are hyperchromatic and have coarsely granular compact chromatin. The cytoplasm is scant, resulting in nuclear molding. Mitotic activity is high. (Hematoxylin-eosin stain, yellow bar: original magnification.)

In recent years, it has become clear that neuroendocrine carcinomas are not limited to the small sized tumor cells. Poorly differentiated large cell carcinomas may express neuroendocrine differentiation by immunohistochemistry. These large tumor cells have nuclear characteristics common to neuroendocrine carcinoma, namely coarsely granular chromatin (Fig. 9A). However, the nucleoli vary from indistinct to medium size. In addition to the diffuse infiltrative pattern, tumor cells are also arranged in trabeculae, ribbons, and rosettes, and the cytoplasm varies from scant to moderate in amount. In a recently proposed classification, neuroendocrine carcinomas are divided into small (Fig. 9) and large cell types.22

Fig. 9. Neuroendocrine carcinoma. (A) Tumor cells have small oval and elongated hyperchromatic nuclei with coarsely granular chromatin. The nucleoli are small or absent. There is a small amount of eosinophilic cytoplasm. (B) Same tumor is diffusely immunoreactive for CD56. (Hematoxylin-eosin stain, red bars: original magnification.)

 

 

 

 

 

All poorly differentiated small cell and large cell carcinomas with the above morphologic features should be studied by immunohistochemistry for neuroendocrine markers (neuron-specific enolase, chromogranin, synaptophysin, CD56; Fig. 9B). By immunohistochemical stains, 20–100% of small cell anaplastic carcinomas were reported to express neuroendocrine differentiation.22, 27 This subset is classified as small cell neuroendocrine carcinoma. Neuroendocrine carcinomas sometimes coexist with adenocarcinoma or squamous carcinoma.

Small cell anaplastic carcinomas are believed to derive from multipotential cell or argyrophilic cells in the basal cell layer of the endocervical mucosa.30 This tumor has a propensity to occur in young women (mean age, 36 years vs 50 years in patients with small cell squamous carcinoma),31 a strong association with HPV type 18,32 and aggressive behavior.31, 33 When treated with radical hysterectomy and pelvic nodal dissection, four of six (67%) patients with small cell anaplastic carcinoma had pelvic nodal metastasis and five of eight (63%) patients developed tumor recurrence, compared with 18% nodal metastasis and 9% tumor recurrence in women with small cell squamous carcinoma.34 Spread beyond the uterus and pelvis is common even for stage I tumors. It is recognized as one of the most aggressive types of cervical cancer with a 5-year survival rate of 14% in one study.33

Sevin and colleagues35 reported 12 women with small cell anaplastic carcinoma, including one FIGO stage IA, ten stage IB, and one stage II. When compared with stage IB and II cervical squamous carcinoma and adenocarcinoma combined, small cell anaplastic carcinoma had a higher frequency of vascular lymphatic space invasion (82% vs 62%), more frequent lymph node metastasis (45.5% vs 18.9%), and a lower 5-year survival rate (36.4% vs 71.6%). Only 42% (5 of 12) of patients were disease free at the time of report. In view of these findings, a combined therapy of surgery, radiotherapy, and cytotoxic chemotherapy is recommended.35

The value of separating squamous carcinoma by cell type was evaluated using the data of the Gynecologic Oncology Group (GOG). Among women with stage I squamous carcinoma treated surgically, the cell type was not predictive of pelvic nodal metastasis and outcome.36, 37 The percentages of patients progression-free at 5 years were 84% for large cell keratinizing and 74% for large cell nonkeratinizing (p = not significant), and 75% for grade 1, 82% for grade 2, and 78% for grade 3 (p = not significant).36

The consistency and reproducibility among pathologists in separating large cell keratinizing and nonkeratinizing tumors based on cervical biopsy specimens cause problems in interpretation. In the GOG study of women with IIB–IVA squamous carcinoma treated by radiation therapy, when the histologic criteria were modified to include all tumors with individual cell keratinization in the large cell keratinizing category, this group had a significantly higher recurrence/death rate than the large cell nonkeratinizing group (65.8% vs 53.5%, p = 0.0074).38

Histologic grade

The histologic grade reflects the degree of differentiation of the tumor cells. The most commonly used grading system for squamous carcinoma is a modification of the original Broders' system consisting of three grades based on the amount of keratin, the degree of nuclear atypia, and the mitotic activity. Grade 1, well-differentiated lesions exhibit abundant intercellular bridging, cytoplasmic keratinization, and keratin pearls. The cells are relatively uniform with minimal nuclear pleomorphism. The mitotic rate should be less than two per high-power field.24 Grade 2, moderately differentiated lesions show primarily individual cell keratinization, moderate nuclear pleomorphism, and up to four mitotic figures per high-power field.24 Grade 3, poorly differentiated lesions show little evidence of squamous differentiation. The tumor cells are immature, with marked nuclear pleomorphism, scant cytoplasm, and more than four mitotic figures per high-power field.24

In surgically treated patients with stage I and II squamous carcinomas, some studies have found histologic grade to influence prognosis and pelvic nodal metastasis.37 In the study of stage I squamous carcinoma from GOG, the histologic grade was correlated with the frequency of pelvic nodal metastasis. Pelvic nodal metastasis occurred in 9.7%, 13.9%, and 21.8% of grade 1, grade 2, and grade 3 tumors, respectively.37 Comparable results were reported by Fuller and colleagues39 (Table 5). Some investigators of stage IB and IIA carcinomas have found that grade 3 tumors were larger and had a higher incidence of lymph node metastasis than lower-grade lesions.39 Fuller and colleagues39 found that 25% of grade 3 tumors had pelvic lymph node metastases, compared with 9% and 16% in grades 1 and 2 tumors, respectively. Another study showed that among 445 patients with stage IIB through IVA squamous carcinoma treated by radiation therapy following GOG protocols, the histologic grade had no impact on prognosis.38 Similar findings were reported by others.40, 41

Table 5. Frequency of lymph node metastasis in surgically treated cases

 

Delgado et al.37 (745 stage I squamous carcinoma >3 mm in depth)

Fuller et al.39 (431 IB and IIA squamous carcinoma, adenocarcinoma, and others)

FIGO stage

I

15.5%

IB

15%

   

IIA

22%

Stromal invasion

3–5 mm

3.4%

<1/3

0%

 

6–10 mm

15.1%

2/3

12%

 

11–15 mm

22.2%

>2/3

24%

 

16–20 mm

38.8%

  
 

21 mm

22.6%

  

Lymphatic vascular space invasion

Absent

8.2%

Absent

14%

 

Present

25.4%

Present (lymphatic)

36%

Parametrial disease

Absent

13.5%

Not evaluated

 
 

Present

25%

  

Tumor size

Occult

8.9%

  
 

Gross

20.9%

  

Histologic grade

Grade 1

9.7%

Grade 1

9%

 

Grade 2

13.9%

Grade 2

16%

 

Grade 3

21.8%

Grade 3

25%

Cell type

LCK

17.2%

Squamous carcinoma

18%

 

LCNK

17.2%

Adenocarcinoma

18%

 

Small cell and others

17.6%

Adenosquamous carcinoma

17%


LCK, large cell keratinizing; LCNK, large cell nonkeratinizing.

In the early 1980s, a malignancy grading system (MGS) was proposed as an alternative grading system.42 In the MGS system eight morphologic parameters of a tumor, consisting of four characteristics of the tumor cell population (structure [i.e., papillary vs solid], degree of cell differentiation, nuclear pleomorphism, and mitotic activity) and four characteristics of the tumor–host relation (mode of invasion, stage of invasion, extent of vascular invasion, degree of host inflammatory response [lymphoplasmacytic]) are evaluated and scored on a one- to three-point scale with a minimum score of 8 points and a maximum score of 24 points.42 When this grading system was applied to 445 IIB–IVA squamous carcinoma patients treated by radiation therapy, the recurrence/death rates were 32.9% for women whose tumors scored up to 12 points, 57.3% for tumors scoring 14–16 points, and 64.8% for neoplasms with scores of more than 18 points (p = 0.004).38

From a practical point of view, histological type, depth of invasion, lymphovascular invasion, and tumor stage are the most important parameters to guide clinical management.

Variants of squamous carcinoma

Verrucous squamous carcinoma of the cervix, like that of other sites, represents a special variant of well differentiated squamous carcinoma. Grossly, these tumors appear exophytic and warty, and may simulate a condyloma acuminatum. Histologically, the cells in this variant show orderly maturation and lack cytologic atypia. The tumor grows by expansion with smooth pushing margins, as opposed to the infiltrating pattern of conventional squamous carcinoma.

To differentiate verrucous squamous carcinoma from either condyloma, pseudoepitheliomatous hyperplasia or typical squamous carcinoma, full-thickness biopsy specimens are necessary. Some squamous carcinomas have a verrucous appearance, but show severe nuclear atypia and foci of invasion by nests or single cells. These tumors behave like conventional squamous carcinoma and should be identified as such. Condyloma acuminatum has prominent koilocytosis and delicate fibrovascular cores, as opposed to the compressed cores and confluent epithelial growth pattern seen in verrucous squamous carcinoma. Condylomas also lack the expansile, endophytic extension into the stroma seen in verrucous squamous carcinomas.

None of at least 18 cases of verrucous carcinoma reported in the literature had lymph node metastasis. Direct extension into the vagina occurred in six women and the endometrium in three cases. About 40–50% had local recurrence, due to either incomplete excision or resistance to radiation therapy.43

Papillary squamous carcinoma of the cervix is characterized by highly dysplastic squamous cells forming papillary fronds with thin fibrovascular cores (Fig. 10). Not surprisingly, the gross appearance of this lesion may be warty or fungating as in verrucous squamous carcinoma. In recent years, terms such as papillary squamotransitional cell carcinoma and transitional cell carcinoma have been used.44, 45 Although there is some morphologic resemblance to the poorly differentiated transition cell carcinoma of the urinary bladder, by immunostains, only two of 21 (9.5%) tumors expressed a distinct marker of transitional cells, cytokeratin 20. Thus, these tumors are of squamous cell type.44

Fig. 10. Papillary squamous carcinoma. (A) Multiple papillary fronds are supported by delicate fibrovascular cores. (B) Close view of papillary squamous cell carcinoma with features of transitional cell differentiation. (Hematoxylin-eosin stain, red bars:original magnification.)

 

 

 

 

In a series of 32 women, the age of patients with papillary squamous cell carcinoma varied from 22 to 93 years (mean 50 years).44 The women presented with abnormal bleeding or abnormal cervical smears. The tumor size ranged from 0.7 to 6 cm (mean 3.0 cm). The diagnostic problems are indicated by the fact that only 20 of 32 (63%) specimens were considered to be adequate. The remaining 37% were too superficial to determine whether they were in situ or invasive carcinoma. Of those with suitable specimens, 90% (18 of 20) had stromal invasion.44 Since invasion is evident only in the stroma beneath the papillary surface components, full-thickness biopsy specimens are necessary to distinguish in situ from invasive lesions.

In a series of nine cases, one tumor was an in situ lesion, whereas the remaining eight cases ranged from stage I to stage IV invasive carcinoma.46 In another study, the FIGO stage was known in 11 women, including two stage 0, three stage IA, two stage IB, one stage IIA, one stage IIB, and two stage IIIB.44 In this series, only 12 women had follow-up information, three patients died all stage IIB or higher, and the mean survival was 13 months after diagnosis.44 One patient developed ovarian metastasis, one patient had vaginal recurrence 12 years later, and in one patient, adenosquamous carcinoma of the endometrium occurred. Five women were alive and well, and three died of other causes. Late recurrence and metastasis were known to occur.46

Circumscribed carcinoma of the uterine cervix was described in 1977 by Hasumi and associates.47 In their study, the tumors were characterized by solid cords of cells with neither squamous nor glandular differentiation, surrounded by a dense lymphocytic infiltrate, which occasionally contained a considerable number of eosinophils and plasma cells. The tumor cells were fairly monomorphic, with large nuclei, one or more nucleoli, and clear to eosinophilic, granular cytoplasm. Many mitotic figures were seen. All 39 cases reported measured larger than 5 mm in depth, but only two (5%) had lymph node metastases at the time of surgery, compared with 18% of ordinary squamous carcinomas of comparable stage. Improved 5 year survival was also seen in these cases (97% vs 79%, p <0.05).47

Studies of similar, if not identical, tumors use the term lymphoepithelioma to indicate the histologic likeness to the lymphoepithelioma of the nasopharynx and the malignant lymphoepithelial lesions of the salivary glands.48, 49 In a study by Tseng and associates,50 15 such tumors were compared with the conventional squamous carcinomas by polymerase chain reaction (PCR). Epstein–Barr viral gene sequences were found in 11 of 15 tumors (73%), compared with four of 15 (27%) of the usual squamous carcinomas (p = 0.001). Interestingly, HPV 16 and 18 types were detected in 20% (three of 15) of these tumors, compared with 80% (12 of 15) of the usual squamous carcinomas (p = 0.001).50

Although the total number of cases in the literature is too small for complete understanding of these neoplasms, they appear to have a better prognosis than the conventional squamous carcinoma. After radical hysterectomy all 15 patients were alive and well.50

Spindle cell squamous carcinoma is a rare variant of poorly differentiated carcinoma that may be confused with either melanoma or sarcoma.5, 51 This tumor is composed of cells with large, spindle shaped, or oblong nuclei arranged in fascicles (Fig. 11). Keratin formation and the nesting pattern typical of epithelial tumors may be absent. Stromal changes such as heavy collagen deposition may give the appearance of a fibrosarcoma or osteosarcoma. When confronted with such a lesion, electron microscopic examination or immunohistochemistry is often required to identify the epithelial nature. A positive immunohistochemical stain for cytokeratin and the demonstration of desmosomes and tonofilaments by electron microscopy distinguish these lesions from mesenchymal tumors.

Fig. 11. Squamous carcinoma, spindle cell type. Elongated tumor cells are arranged in bundles simulating spindle cell sarcoma. Immunohistochemical stain for cytokeratin is positive to confirm carcinoma (not shown). (Hematoxylin-eosin stain, red bar: original magnification.)

 

 

 

 

 

One may also rarely see abnormal spindle cells in the cervical stroma adjacent to typical squamous carcinoma. This so called pseudosarcoma was reported by Watty and colleagues52 who described individual atypical stromal cells with elongated, pleomorphic nuclei and frequent multinucleation. Rare abnormal mitotic figures were seen. The authors felt that this change represented a response to the nearby tumor and noted that similar lesions have been reported in squamous carcinomas of the head and neck region.

CERVICAL GLANDULAR PRECANCER LESIONS

Endocervical dysplasia and adenocarcinoma in situ

Recognitions of endocervical adenocarcinoma in situ is important for the clinical management of patients and for the risk of recurrence and tumor progression. However, the distinction of endocervical glandular lesions among benign, dysplastic, and truly carcinoma in situ of endocervix can be challenging and sometimes very difficult. Silverberg SG et al.53 established a three tier scoring system to differentiate the benign and dysplastic endocervical lesions from endocervical adenocarcinoma in situ. This new scoring scheme gives scores from 0 to 3 to each lesion for: (1) nuclear atypia, (2) stratification, and (3) sum of mitoses/apoptoses (counted in the two most active glands, and the average number used). These three scores are then added to result in the total score (0–3 = benign; 4–5 = endocervical glandular dysplasia; 6–9 = adenocarcinoma in situ) (Table 6). Without using the score system, agreement between five observers in the first round review of 67 endocervical glandular lesions was in 52% (35 of 67 cases), while using the score system, agreement of the second round review can be 94% (63 of 67 cases), meaning that the scheme affords accurate distinction between adenocarcinoma in situ and lesser lesions. Some immunomarkers, including Ki-67 and p16 can also be useful in the diagnosis of endocervical andocarcinoma in situ (Fig. 13D).54

Table 6. Score system for glandular dysplasia and carcinoma in situ53

 Scores Mild Moderate Severe
 Nuclear atypia 1 2 3
 Stratification 1 2 3
 Sum of mitoses + apoptoses in 2 glands/2 1 2 ≥3
  
 Benign                               
 0–3
 Endocervical glandular dysplasia  4–6
 Endocervical carcinoma in situ  7–9

Adenocarcinoma in situ

Morphologic changes less severe than adenocarcinoma in situ have been described and designated as glandular atypia or glandular dysplasia (Fig. 12).5, 17 These lesions are detected in specimens removed for adenocarcinoma in situ or cytologic diagnosis of atypical glandular cells of undetermined significance. In the endocervical curettage specimens and cervical biopsy specimens, atypical endocervical cells present with nuclear enlargement, irregularity, and multinucleation in a background of chronic cervicitis. The adjacent squamous mucosa may have condyloma or low-grade dysplasia.5, 17 These changes are probably reactive atypia and do not have malignant potential. On the other hand, dysplastic glands lined by endocervical cells with moderate or more severe degrees of nuclear atypia, enlarged hyperchromatic nuclei, two to three stratified layers and increased mitotic activity are potential precursors of adenocarcinoma. Dysplastic change also occurs in glands lined by ciliated tubal metaplastic cells. The morphologic criteria and biologic potential of glandular dysplasia remain to be defined.

Fig. 12. Endocervical glandular dysplasia. (A) H/E stained slide shows focal area of atypical glandular epithelium with partial stratification, moderate nuclear atypicality, and  one mitosis. (B),(C) Immunostains reveal an increase of Ki-67 index (B) and focal immunoreactivity for p16 (C). (Yellow bars: original magnification).

 

 

 

The entity of cervical adenocarcinoma in situ has been widely accepted and recognized as the precursor of invasive adenocarcinoma. Endometrioid17 and clear cell types14 of adenocarcinoma in situ have also been described. More than 50% of adenocarcinomas in situ were found to have coexisting squamous dysplasia or carcinoma in situ. When squamous carcinoma in situ contains mucus secreting cells, Steiner and Friedell55 designated the lesion as adenosquamous carcinoma in situ.

The majority of adenocarcinomas in situ are detected initially in the cervical smears of asymptomatic women or incidentally in hysterectomy specimens removed for benign conditions. Some are found in cervical biopsy specimens, endocervical curettage specimens, or cone specimens removed for squamous neoplasia. Colposcopic findings are nonspecific, such as patchy acetowhite lesions in the cervical canal, fused and papillary columnar villi, and abnormal vessels.

Most adenocarcinomas in situ begin in the region of the squamocolumnar junction and spread proximally (Fig. 13A). With few exceptions, both the endocervical mucosal surface and the underlying glands are involved. The affected surface may be flat, papillary or villous in appearance. The neoplastic glands form budding and crowded back to back glands (Fig. 13A–C). Excessive proliferation within large glands sometimes results in a cribriform pattern. The most characteristic features are the preservation of normal branching patterns, the smooth configuration of the glandular profiles and normal fibromuscular stroma without desmoplasia (Fig. 13).

Fig. 13. Endocervical adenocarcinoma in situ. (A) The neoplastic endocervical glands retain the branching and budding pattern of normal endocervical glands. These glands have smooth borders and are surrounded by normal fibromuscular stroma without desmoplastic reaction. At the base of the tumor, malignant cells replace normal endocervical cells. (B),(C) Higher magnification to reveal tall columnar neoplastic cells with nuclear stratification (B), hyperchromasia, elongation, irregularity (C), and increased mitoses (B),(C). (Hematoxylin-eosin stain, yellow bars: original magnification). (D) The neoplastic glands are diffusely immunoreactive for p16. 

 

 

 

Over 80% of cervical adenocarcinomas in situ are made up exclusively or predominantly of mucus-secreting endocervical cells.5 Endometrial cells, intestinal cells, and clear cells occur in the remaining 20%. Normally, endocervical cells are arranged in a single layer and have basally located small nuclei. Nucleoli and mitotic figures are absent or rarely observed. Neoplastic endocervical cells demonstrate nuclear pseudostratification, enlargement, hyperchromasia, and elongation (Fig. 13). Nucleoli are multiple and mitotic figures are easily identified. The cytoplasm appears basophilic, clear or vacuolated. In the deeper portion of the endocervical glands, a sharp transition between the normal and neoplastic cells is apparent.

Squamous cell dysplasias and carcinomas in situ coexist with 35–71% of adenocarcinomas in situ (Fig. 14).34, 56, 57 Rarely, microinvasive squamous carcinoma has been recorded.34 The squamous and glandular elements often merge into one lesion.

Fig. 14. This cervical cone biopsy reveals coexisting adenocarcinoma in situ (right) and severe squamous cell dysplasia (left). (Hematoxylin-eosin stain, yellow bar: original magnification.)   






 

Adenosquamous carcinoma in situ

The entity of adenosquamous carcinoma in situ described by Steiner and Friedell55 closely resembles squamous cell carcinoma in situ. Intermixed with the dysplastic squamous cells, however, are cells with vacuolated or basophilic cytoplasm. Mucicarmine and periodic acid-Schiff (PAS) stains reveal mucin production in these cells (Fig. 15). Similar change sometimes occurs in the vicinity of adenosquamous carcinomas.

Fig. 15. Adenosquamous carcinoma in situ. Nests of noninvasive squamous cell carcinoma with luminal glandular cell components (pink intracytoplasmic mucin detected by counterstain of Mucicarmin). (Hematoxylin-eosin stain, red bar: original magnification.)  







Although the diagnosis of adenocarcinoma in situ may be made on the basis of cytology and biopsy specimens, it is difficult to separate in situ from well-differentiated invasive adenocarcinoma. As both lesions may occur concurrently, cervical conization is usually performed for a definitive diagnosis.

Estimates based on conization and hysterectomy specimens have found adenocarcinoma in situ extending as deep as 3–5 mm from the mucosal surface. The linear extent along the cervical canal varies from 0.5 to 25 mm with a mean of 12 mm.58 If measured from the external os, these lesions may reach up to 30 mm.59 This implies the need for deep conization to encompass the entire lesion. Young women, who prefer to retain the uterus, may be treated by conization alone and followed regularly by endocervical aspiration or curettage.58 However, even if the surgical margins of the conization specimen appear uninvolved, residual tumors may exist. A possible explanation for this is a multifocal disease, which is estimated to occur in 15%.58

The importance of assessing surgical margins of conization specimens is emphasized in the study of Wolf and associates.57 They studied 61 women (mean age 35.9 years) with adenocarcinoma in situ. Of the 55 women who underwent cone biopsies, 50 had known status of cone margins, and 44 had subsequent hysterectomies. The conization margins were positive in 23 of 50 (46%) women, and 19 of these had hysterectomies. A residual tumor was found in ten of 19 (53%) hysterectomy specimens, including adenocarcinoma in situ in four, invasive adenocarcinoma in five, and glandular atypia in one.57 Three of four women, who received no further treatment, were well for 2–9 years. The fourth woman was lost to follow-up.57

The conization margins were negative in 27 of 50 patients (54%), and 21 had had hysterectomies. A residual tumor was found in seven of 21 (33%) cases, including invasive adenocarcinoma in three (two neoplasms 2 mm or less, one tumor 5 mm), adenocarcinoma in situ in three, and glandular atypia in one.57 Of six women who refused hysterectomy after cone biopsy, two were lost to follow-up, one developed 5-mm-deep invasive adenocarcinoma 2 years after the cone biopsy, one developed glandular atypia which was treated by cone biopsy, and the remaining two have no evidence of disease.57 These findings provide sufficient evidence of the malignant nature and the multifocality of adenocarcinoma in situ. When treated by conization alone, a close follow-up with endocervical samples is recommended.

MALIGNANT GLANDULAR NEOPLASMS

Cervical carcinomas with glandular differentiation are of heterogeneous cell types, diverse growth patterns, and variable differentiation. The majority of glandular neoplasms are pure adenocarcinomas. As many as 25–50% of cervical adenocarcinomas contain malignant squamous elements.5 Of these, adenoid cystic carcinoma and adenoid basal carcinoma are sufficiently distinct to be recognized as separate entities. A simplified histologic classification of invasive glandular neoplasms according to the cell type is listed below.

Endocervical adenocarcinoma

  1. Endocervical type:
    a. Usual type;
    b. Minimal deviation adenocarcinoma (adenoma malignum);
    c. Well-differentiated villoglandular adenocarcinoma;

  2. Endometrioid type
  3. Clear cell type
  4. Papillary serous type
  5. Intestinal type
  6. Mesonephric type
  7. Mixed type

Adenosquamous carcinoma

  1. Mature type;
  2. Signet-ring type (mucoepidermoid carcinoma);
  3. Glassy cell type

Adenoid cystic carcinoma

Adenoid basal carcinoma

Microinvasive adenocarcinoma

Several investigators have attempted to define the morphologic criteria for microinvasive adenocarcinoma. Teshima and associates60 defined early adenocarcinoma as less than 5 mm of stromal invasion measuring from the mucosal surface (Fig. 16). All 30 patients in this study were treated by hysterectomy and one woman developed tumor recurrence. This patient had a tumor, which was 3 mm in depth, did not involve the capillary-lymphatic spaces or pelvic lymph node, but recurred in the vaginal cuff. Buscema and Woodruff61 also reported a 3 mm deep, adenosquamous carcinoma that metastasized widely. Among women with stage I and II cervical adenocarcinoma up to 5 mm in depth, Berek and colleagues62 found that two (8%) of 24 women had pelvic lymph node metastasis and the overall 5-year survival rate was 92%. Thus, adenocarcinomas as superficial as 5 mm have a small risk of pelvic nodal metastasis. 

Fig. 16. Endocervical adenocarcinoma. The section illustrates a cone biopsy specimen with neoplastic endocervical glands extending more than 3 mm deep into the stroma from the mucosal surface. Despite no apparent desmoplastic reaction and no cribriform growth pattern, cytological changes and depth of involvement fits the diagnosis of microinvasive adenocarcinoma. (Hematoxylin-eosin stain, yellow bar: original magnification.)

 

 

 

 

 

 

 

 

In a recent study of 77 early invasive adenocarcinomas by Ostor and associates,63 microinvasive adenocarcinoma was defined as less than 5 mm in depth. The invasive tumor was measured from the mucosal surface to the deepest point of the tumor. This type of measurement is referred to as tumor thickness by other authors. The tumor thickness was 0.1–1.1 mm in 12 cases, 1.1–2.0 mm in 12 cases, 2.1–3.0 mm in 19 cases, 3.1–4.0 mm in 22 cases, and 4.1–5.0 mm in 12 cases. The histologic type of these tumors is heterogeneous, including adenocarcinoma in situ with early stromal invasion, well-differentiated adenocarcinoma, and papillary villoglandular adenocarcinoma. Seven (9%) tumors had vascular lymphatic space invasion, and 21 (27%) neoplasms had multifocal lesions involving both cervical lips. Other findings showed 66% of women had abnormal glandular cells in the Pap smear, 38% had abnormal colposcopic findings, and 53% had used oral contraceptive pills.63

Treatment modalities in the study of Ostor and associates63 included cold-knife conization and simple to radical hysterectomy. There was no parametrial involvement in any of the 26 radical hysterectomy specimens. Pelvic lymph nodes in 48 women undergoing nodal sampling were all negative. Twenty-three women had one or both ovaries removed, and all were free of tumor.63 Two women had tumor recurrence. The first, a 62-year-old woman whose original tumor was 3.2 mm in depth, 21 mm in length, and 670 mm3 in volume had a total abdominal hysterectomy, bilateral salpingo-oophorectomy, and external pelvic irradiation. Five years later, she developed recurrent tumor in the vaginal vault, which was excised. Four years later, tumor recurred in the vault and was treated by upper vaginectomy. This patient died postoperatively. In the second woman, the original tumor was 5 mm in depth, 10 mm in length, and 450 mm3 in volume. Nine years following total abdominal hysterectomy, squamous carcinoma was found in the vaginal vault.63

The study of Ostor and associates63 provides an alternative approach to express the extent of stromal invasion by measuring from the surface of the lesion to the deepest point of tumor in the form of tumor thickness. However, not all early invasive adenocarcinomas arise from the mucosal surface. Isolated foci of invasion sometimes take place from the periphery of endocervical glands involved by adenocarcinoma in situ (Fig. 17). These glands may be superficial or deep. How to measure these tumors remains to be clarified. In addition, glandular tumors that are less than 5 mm in depth, but have potential to metastasize, such as poorly differentiated adenocarcinoma, serous carcinoma, and adenosquamous carcinoma, are best excluded from the microinvasive category.

Fig. 17. Microinvasive adenocarcinoma. This small focus of microinvasive adenocarcinoma forms multiple, irregular tongue-like protrusions from the periphery of endocervical glands. These protrusions are associated with fibrotic stroma and chronic inflammation. (Hematoxylin-eosin stain, red bar: original magnification.)

 

 

 

Invasive adenocarcinoma

The clinical presentation and gross appearance of cervical adenocarcinoma are basically similar to those of squamous carcinoma. In a series of 55 women with IB adenocarcinoma by Greer and colleagues,64 44% of women had no symptoms and 58% (32 of 55) had no gross lesions. The diagnosis was suspected on the basis of abnormal cervical smears in 16 women (29%). Of these, 15 required conization for diagnosis.64

Cervical adenocarcinoma, endocervical type

Depending on the degree of differentiation, the predominant growth pattern may be glandular, mucinous (colloid), papillary, solid or mixed.65 In endocervical adenocarcinoma of the usual type, well-differentiated tumors present with small, back to back glands (Fig. 16). The lining cells have eosinophilic or finely vacuolated pale staining cytoplasm resembling normal endocervical cells. In moderately to poorly differentiated neoplasms, anaplastic cells are arranged in solid nests and some have a signet-ring appearance. Moderately differentiated tumors have a mixture of glands and solid nests (Fig. 18). Tumors with abundant extracellular mucin are referred to as colloid type. The tumor cells resemble endocervical or intestinal type.

 

 

Fig. 18. Cervical adenocarcinoma, endocervical type. Infiltrating adenocarcinoma (upper) is moderately differentiated, represented by small irregular glands and solid nests. Close view of this tumor (lower) shows vacuolated cytoplasm and mucinous appearance. Nuclear atypia is apparent. (Hematoxylin-eosin stain, red bars: original magnification.) 

 

 

An extremely well-differentiated adenocarcinoma closely resembling normal endocervical cells has been designated as adenoma malignum,66 or minimal deviation adenocarcinoma.67 This variant deserves special recognition, because of its difficulty to diagnose. The tumor retains the branching pattern of normal endocervical glands, presents with minimal nuclear atypia and causes minimal stromal responses (Fig. 19). Although similar characteristics have also been observed in well-differentiated endometrioid, clear cell, and mesonephric carcinomas,68 most authors apply the term adenoma malignum66 only to the endocervical type.

Fig. 19.  Cervical adenocarcinoma, minimal deviation type (adenoma malignum). Neoplastic cells form branching, budding glands resembling normal endocervical glands (A). Tumor cells extend into the deep margin of conization specimen. Individual cells also closely mimic normal endocervical cells, having tall columnar configuration and abundant mucinous cytoplasm and basally located, small nuclei (B). On closer examination, nuclear irregularity and small nucleoli become evident. (Hematoxylin-eosin stain, red bars: original magnification.)

 

The possibility of reaching a correct diagnosis is enhanced by the knowledge of cervical abnormality and a deep biopsy. The latter may provide clues as to the subtle irregularity in the size and shape of neoplastic glands. Encroachment of the blood vessels and nerve fibers adds further support for stromal invasion. Careful survey of individual lining cells reveals mild nuclear atypia and uneven chromatin. Nucleoli may be evident (Fig. 20B).

Patients with minimal deviation adenocarcinoma are reported to have a dismal outcome by some,66, 69 but favorable survival rates by others.67, 68 There is no question that the prognosis is strongly governed by the extent of local disease and pelvic nodal status. Patients with stage I or II neoplasm without pelvic nodal metastases are expected to have a favorable outcome following radical hysterectomy. The presence of pelvic nodal metastasis or advanced local disease adversely affects survival. Delay in correct diagnosis may account for some of the advanced cases.

Equally important, benign conditions, such as tunnel clusters of endocervical glands, hyperplastic mesonephric ducts, and endometriosis, should not be confused with minimal deviation adenocarcinoma. Immunoperoxidase stain for carcinoembryonic antigen can be helpful, because this tumor marker is negative in benign changes and positive in minimal deviation adenocarcinoma.70

Young and Scully71 reported a series of 13 villoglandular papillary adenocarcinomas of the uterine cervix. This tumor occurred mostly in young women (mean age, 33 years). The lesions were described clinically as polypoid, condylomatous, eroded, nodular, white, friable or fungating. Microscopically, the superficial portion of tumor consists of complex papillae lined by well-differentiated endocervical cells (Fig. 20). In the deeper portion of the tumors, tumor cells form branching tubular glands pushing into fibrous stroma (Fig. 20). In six women, the tumor was confined to the superficial one third of cervical wall, whereas deep invasion occurred in two women. After hysterectomy, no tumor recurrence was noted in ten women observed for 2–14 years.71

Fig. 20. Cervical adenocarcinoma, villoglandular type. On the surface are multiple papillary projections consisting of columnar cells with either thick (A) or thin (B) fibrovascular cores. The base of the tumor usually has smooth borders without infiltrative pattern. (Hematoxylin-eosin stain, yellow and red bars: original magnification.)

 

 

 

In a subsequent study of 24 cases by Jones and associates,72 the mean age was 37 years (27–54 years), and 50% were in their third decade of life. There was history of oral contraceptive use in 63% of women, this is in contrast to 28% among women having other types of cervical adenocarcinoma (p = 0.02). Grossly, the tumor had an exophytic polypoid appearance. Microscopically, the predominant cell type was endocervical in 50%, endometrioid in 33%, and intestinal cell in 17%. In all, 33% had coexisting squamous dysplasia or carcinoma in situ. Five (21%) tumors were entirely in situ without stromal invasion; 75% (18 tumors) were superficial, confined to the inner third of cervical wall; and 4% (one tumor) invaded 75% of cervical wall.72

Treatment modalities included local excision or cone biopsy in five women, simple hysterectomy in four women, and radical hysterectomy in 15 women.72 All tumors were confined to the cervix without pelvic lymph node metastasis. All women were alive and well 7–77 months (mean 36 months) later. In view of the distinct clinical and pathologic features, these tumors are separated from other cervical adenocarcinomas. A conservative treatment is considered to be justified, especially in young women who want to retain fertility.72

It should be emphasized that the term villoglandular papillary adenocarcinomas should be reserved only for those tumors which meet the stringent morphologic criteria. The degree of nuclear atypia should be no worse than moderate in degree. The tumor borders should be smooth and tumors made up of clear cells and serous cells are excluded. In the cervical biopsy specimens and endocervical curettage specimens, there are fragments of tumor that have villous pattern. However, in the subsequently excised specimens, some of these tumors prove to have poorly differentiated elements or have infiltrative borders. Thus, the diagnosis of well-differentiated villoglandular should be made on completely excised specimens.

Distinguishing endocervical and endometrial adenocarcinomas can be difficult on routinely stained sections. PAS and mucicarmine stains and immunohistochemical stains are helpful in identifying the cell type. Mucinous secretion is evident in endocervical cells by mucicarmine and PAS stains. By immunohistochemistry, these cells frequently express carcinoembryonic antigen (CEA), but are negative for vimentin. Neoplastic endometrioid cells, on the other hand, are negative for cytoplasmic mucin and CEA, but are positive for vimentin (Fig. 21).73, 74 These stains, however, cannot be used to determine the anatomic site of origin. This is because 15% of endocervical adenocarcinomas belong to the endometrioid cell type, and endocervical mucinous metaplasia occurs in as many as 40% of primary endometrial carcinomas.5 Thus, the distinction between endocervical and endometrial tumors often requires additional clinical findings and tissue samples.5

Fig. 21. Endocervical adenocarcinoma, endometrioid type has a similar histology and immunoprofile to its uterine counterpart, represented by pseudostratified nuclei, smooth luminal border (A1) and immunoreactivity for vimentin (A2). Endocervical type (B1) is negative for vimentin(B2). (Hematoxylin-eosin stain, yellow bars original magnification.)

 

 

 

 

 

 

 

 

Cervical adenocarcinoma, endometrioid yype

This group of tumors has the appearance of grade I or grade II adenocarcinoma of the endometrium. The predominant growth pattern is glandular or less commonly papillary. The lining cells are tall, columnar, and have densely basophilic or eosinophilic cytoplasm. The diagnosis is justified only if the endometrium is normal after careful sampling for histologic examination (Fig. 22). Sometimes, mature metaplastic squamous cells occur within the neoplastic glands. These tumors are designated as adenoacanthomas.5, 65  

Fig. 22. Cervical adenocarcinoma, endometrioid type. Infiltrating adenocarcinoma contains tall, columnar cells with pseudostratified nuclei, eosinophilic and basophilic cytoplasm, and an area of squamous metaplasia inside the tumor gland. (Hematoxylin-eosin stain, yellow bars original  magnification.)     

 

 

 

Cervical adenocarcinoma, clear cell type

Cervical clear cell adenocarcinoma affects women with or without exposure to diethylstilbestrol (DES) in utero. The age distribution has a bimodal peak, one around 20 years of age and the other in the fifth and sixth decades of life.75 The most common complaint is vaginal bleeding and, on examination, a polypoid, exophytic or fungating tumor is visible.75, 76 About two thirds are FIGO stage IB and the remaining are stage II or higher.76

In the DES exposed progeny, the cervical clear cell carcinomas are located mainly in the ectocervix and rarely in the endocervix.77

Under the microscope, the tumor cells have distinct clear, empty appearing cytoplasm and enlarged, hyperchromatic nuclei, which project into the apical cytoplasm, the so called hobnail appearance. The clear cytoplasm is attributed to the accumulation of abundant glycogen similar in appearance to that seen in secretory endometrial cells. The cells grow predominantly in tubulocystic, papillary or solid pattern (Fig. 23). This growth pattern is important prognostically. The most favorable outcome is associated with the tubulocystic pattern, followed by the papillary and solid patterns.

Fig. 23.  Clear cell carcinoma of the cervix. This exophytic tumor mass of endocervix is characterized by papillary growth pattern. Tumor consists of fibrohyalinized stroma lined by intermediate to large tumor cells with clear and pink cytoplasm, high grade nuclei and hobnail appearance. (Hematoxylin-eosin stain, yellow bar: original magnification.)     

 

 

 

Depth of stromal invasion, FIGO stage and pelvic nodal status are key prognostic indicators.77 Five-year survival rates are better than 90% for stage I cases. Most patients had tumor recurrence in 3 years. Rare case of recurrence occurred 20 years after therapy. Metastases to the lung and supraclavicular lymph nodes were more common than in squamous carcinoma.77

Cervical adenocarcinoma, papillary serous type

A few cervical adenocarcinomas indistinguishable from papillary serous carcinoma of the ovary have been reported.78, 79 An aggressive behavior was noted.79 The tumor microscopically has a complex pattern of papillae with cellular budding and glands with slit-like spaces. Moderate to severe nuclear pleomorphism is commonly seen (Fig. 24). Occasionally psammoma bodies can be identified. An in situ component may be present. Nearly half of cases exhibit a second admixed pattern, most commonly low-grade villoglandular adenocarcinoma but endocervical, clear cell and endometrioid adenocarcinoma may be admixed. Diagnosis of serous adenocarcinoma of the cervix can be made only when metastasis from ovary, endometrium, and peritoneum are excluded. A helpful point is that serous adenocarcinoma of the cervix is frequently CEA positive in contrast to this tumor when arising in other sites.

Fig. 24. Cervical adenocarcinoma of papillary serous type. Tumor grows in a papillary pattern and has varied sizes of fibrovascular stroma lined by high grade nuclei. (Hematoxylin-eosin stain, yellow bar: original magnification).






 

Cervical adenocarcinoma, intestinal type

Intestinal-type adenocarcinoma is composed of cells similar to those seen in colorectal adenocarcinomas, characterized by the presence of goblet cells. The intestinal type of adenocarcinoma shows glandular and papillary growth patterns (Fig. 25). Neuroendocrine cells and occasionally Paneth cells may be present. Intestinal-type change may be found diffusely or only focally within a mucinous carcinoma. The main differential diagnosis is with metastatic intestinal adenocarcinoma. Primary cervical intestinal-type adenocarcinoma is generally reactive with cytokeratin 7 and unreactive with cytokeratin 20 and Cdx2.

Fig. 25. Cervical adenocarcinoma of intestinal type. Intermediate power shows infiltrating adenocarcinoma with glandular growth pattern. Tumor cells contain abundant intracytoplasmic mucin with indented nuclei. Goblet cells can be appreciated. (Hematoxylin-eosin stain, red bar: original magnification.)

 

 

 

Adenosquamous carcinoma

Glucksmann and Cherry80 subdivided adenosquamous carcinomas into mature, well differentiated (35%) and immature, poorly differentiated (65%) types, the latter of which is further divided into signet-ring (44%) and glassy cell (21%) types. Glassy cell carcinoma is estimated to comprise 2% of all cervical cancer and 13% of glandular neoplasms.80

Adenosquamous carcinoma, mature type

In the mature type, both the glandular and squamous carcinomas are well to moderately well differentiated to be readily recognized without special stains (Fig. 26). In most cases, the squamous components have the appearance of large cell nonkeratinizing type (Fig. 26). Keratinizing and small cell types are less common.5, 65 The cells contain abundant eosinophilic cytoplasm and evidence of individual cell keratinization. Sometimes, the squamous cells have clear cytoplasm with abundant glycogen. Glandular formation is evident in most of the adenocarcinomas.

Fig. 26. Cervical carcinoma of well differentiated adenosquamous type. Nonkeratin squamous cell carcinoma intermixed with luminal mucinous and columnar cell differentiation. (Hematoxylin-eosin stain, red bar: original magnification.)






 

Cervical adenocarcinoma, mesonephric type

Most of the mesonephric duct carcinomas reported earlier belong to the clear cell adenocarcinoma category by current classification. Of the few true mesonephric adenocarcinomas, the tumor cells form glands, tubules or microcysts (Fig. 27). One important diagnostic feature is the presence of eosinophilic hyaline material in the lumen, which is positive with PAS stain and negative with mucicarmine stain. It should be noted that benign adenomatous hyperplasia of the mesonephric duct can be found deep in the cervical stroma, mimicking adenoma malignum and mesonephric adenocarcinoma.81

 

Fig. 27.  Cervical adenocarcinoma of mesonephric type. Tumor consists of packed tubules and microcysts with infiltrating border (A). A close view of tumor cells shows hyperchromatic and crowded nuclei with frequent mitoses (B). Intraluminal eosinophilic hyaline materials are evident. (Hematoxylin-eosin stain, red bar: original magnification.)

 

 

 

Clement and associates82 reported on a series of eight women 34–71 years of age (mean 54.5 years) who complained of vaginal bleeding. These tumors presented with a variety of growth patterns, including ductal, tubular, retiform, solid, and sex cord-like structures. Rarely, spindle cells resembled endometrial stromal sarcoma and contained osteoid and chondroid metaplasias.82 All tumors were stage IB. Two of five women underwent pelvic nodal dissections had micrometastases.82 Follow-up data indicated that three women were alive and well, two experienced recurrences, and one died of unrelated clear cell carcinoma of the ovary.82

Adenosquamous carcinoma, signet-ring type

This tumor consists of solid nests and sheets of tumor cells resembling nonkeratinizing squamous cell carcinoma. On closer examination, there are additional cells, which have basophilic, vacuolated or clear cytoplasm and compressed nuclei, resembling signet-ring cells.5, 65 With the mucicarmine stain, the presence of mucinous product can be confirmed. Some of the tumors reported as “mucoepidermoid carcinoma”83 and “squamous cell carcinoma with mucin secretion” by Benda and associates84 and Ireland and colleagues85 fall into this category.

In the study by Benda and associates84 69 consecutive IB cervical cancers, including 55 (80%) squamous carcinomas, 12 (17%) adenocarcinomas, and two (3%) undifferentiated carcinomas, were stained by mucicarmine and PAS stains. Eighteen (33%) of 55 squamous carcinomas contained mucin in the cytoplasm. If these are accepted as mixed carcinoma, only 54% (37) of tumors remain in the squamous category (35% keratinizing, 16% nonkeratinizing, 3% small cell) and the frequency of mixed carcinoma is increased to 26%. This distinction is important as there is a difference in the risk of pelvic nodal metastasis. Six (33%) of 18 squamous carcinomas with mucin production had pelvic lymph node metastasis, compared with only two (5%) of 37 squamous carcinomas without mucin (p = 0.01).84 In a separate series of 23 squamous cell carcinomas studied by PAS and Alcian blue stains for mucin, only two (25%) of eight women whose tumors demonstrated cytoplasmic mucin were alive after 3 years. In contrast, 13 (87%) of 15 women whose tumors lacked mucin survived (p <0.01).85 These findings suggest that squamous cell carcinoma with mucin production has a more aggressive behavior than conventional squamous cell carcinoma.

Adenosquamous carcinoma, glassy cell type

Tumor cells of this type have abundant, eosinophilic, granular, and ground-glass cytoplasm, sharp cell borders, uniformly round to oval nuclei, and giant nucleoli. Mitotic figures are abundant (Fig. 28). Many eosinophils and plasma cells are noted in the stroma. In the original description of this entity,80 tumor cells had PAS positive material but no mucinous substance. However, in the study by Maier and Norris86 seven of eight tumors studied by the mucicarmine stain were positive. Three of eight neoplasms contained glandular lumens, and three others had squamous differentiation. One tumor had both glandular and squamous foci. By electron microscopic study, the glassy appearance corresponded to abundant polyribosomes and rough endoplasmic reticulum. The tonofilaments were scant.87 Although no intracytoplasmic lumens were identified, there were intercellular spaces lined by microvilli to suggest glandular differentiation. Some tumor cells also contained mucinous material in the cytoplasm.87 These histochemical and ultrastructural findings support the poorly differentiated nature of these neoplasms and the presence of glandular differentiation in some of the tumor cells.87 Tumor cells are reactive for low and high molecular cytokeratin, MUC1 and MUC2, but negative for estrogen or progesterone receptors.

Fig. 28. Adenosquamous carcinoma of glassy cell type. (A)Tumor consists of sheets of large cells with abundant amphophilic "ground-glass" cytoplasm and well defined cell borders. Areas of glandular structures (left upper corner) can be appreciated. (B)Nuclei are large and relatively uniform with vesicular chromatin and macronuceleoli. Significant inflammatory infiltrate is present. (Hematoxylin-eosin stain, red bars: original magnification.) 

 

 

 

Adenoid cystic carcinoma

Adenoid cystic carcinoma of the female lower genital tract occurs most commonly in the Bartholin gland. This is followed by the uterine cervix, affecting primarily postmenopausal women in their seventh decade of life, about 20 years later than squamous carcinoma. The histologic features are similar to those occurring in the salivary gland. It is suggested that multipotential reserve cells in the endocervical glands acquire myoepithelial differentiation, which is not normally seen in the cervix.

Histologically, basaloid cells are typically arranged in cribriform glands with hyaline or mucinous material in the microcystic spaces. Tubules and solid nests are less common (Fig. 29). Tumors with predominantly solid growth patterns may metastasize early. The individual cells have scanty cytoplasm and small, uniform, hyperchromatic nuclei. Mitotic figures are variable depending on the degree of differentiation.88

Fig. 29. Adenoid cystic carcinoma of the cervix. This infiltrating carcinoma displays large nesting and solid growth patterns. Basaloid cells form most cribriform glands with amphophilic hyaline materials in the lumen. (Hematoxylin-eosin stain, red bar: original magnification.)

 

 

 

 

In about 50% of cases, squamous differentiation is apparent. In such cases, squamous cells replace the glandular lumens partially or completely. When squamous elements predominate, adenoid cystic carcinoma may not be recognized in a small biopsy specimen. Adenoid cystic carcinoma may also be associated with squamous carcinoma in situ; because of this, some women are detected initially by abnormal cervical smears. Other types of adenocarcinoma, undifferentiated carcinoma, or sarcoma may sometimes coexist with adenoid cystic carcinoma.88, 89

In one study, 3–5-year survival rates for patients with stage I adenoid cystic carcinoma were 56% compared with 27% for stage II. None of the patients with stage III or IV disease survived.90 Most of the treatment failures were caused by distant and/or local pelvic recurrence. Metastases occurred most frequently in the lung (44%) and less commonly in the bone, liver, and brain. With only 32% of patients free of disease at last follow-up, the overall prognosis of adenoid cystic carcinoma is worse than that of squamous carcinoma or pure adenocarcinoma of the cervix.90 In a recent review, bulky early stage tumors are best treated with combined surgery and postoperative radiation therapy and chemotherapy with cisplatin.91

Adenoid basal carcinoma

This rare cervical tumor closely mimics basal cell carcinoma of the skin in its histologic appearance. Most patients are postmenopausal and asymptomatic. The cervix is grossly normal and lesions are detected initially by abnormal cervical smears. Microscopically, basaloid cells with scanty cytoplasm and uniformly small, round nuclei are arranged in solid nests. These nests are grouped together in a lobular pattern. Cells in the outermost layer have a distinct palisaded nuclear arrangement. Tubules and cribriform glands with mucinous material are prominent in some cases. Squamous metaplasia may occur (Fig. 30). Mitotic activity is absent to less than one mitotic figure per nest.88 Vascular lymphatic invasion was not seen in any of the cases reported.88

Fig. 30.  Adenoid basal carcinoma of the cervix. This tumor consists of small basaloid nests (left) and  large nests in a lobule with apparently squamous metaplasia (right). Basaloid tumor cells are small with scant cytoplasm and palisaded nuclear arrangement. The nests of large tumor cells are characteristic for squamous cell metaplasia with keratin production. (Hematoxylin-eosin stain, red bar: original magnification.)





 

Most adenoid basal carcinomas have coexisting squamous severe dysplasia or squamous carcinoma in situ. Microinvasive squamous carcinoma may evolve from the periphery of solid nests replaced by neoplastic squamous cells. All reported cases were FIGO stage IA or IB. The prognosis is excellent following hysterectomy. In a review of 26 cases reported in the literature, 85% of patients were alive without tumor recurrence. Three women (12%) died of other causes. Only one case is known to have died of disease with metastasis in the lung.92

The differential diagnosis includes adenoid basal hyperplasia which occurs in the superficial endocervical glands. Adenoid cystic carcinoma presents with infiltrative cribriform glands associated with extracellular mucinous material or hyaline cylinders. Cytologic atypia is evident in the tumor cells. In the case of rare basaloid squamous carcinoma, the tumor cells are cytologically malignant and mitotically active. The infiltrative tumor nests are surrounded by desmoplastic stroma sometimes hyalinized to simulate hyaline cylinders.

In a study of five cases of adenoid basal carcinoma by Jones and colleagues,93 HPV DNA type 16 was detected in all tumors studied by PCR. No K-ras-2 point mutation was detected. One tumor had a point mutation of P53, and four others had weak reaction of P53 and two of these expressed WAF1 (an effector protein induced by wild-type P53). Grayson and associates94 studied nine tumors by nonisotopic in situ hybridization (NISH) and PCR using E6 consensus primers to HPV. HPV DNA type 16 was detected in four tumors (44%) and HPV 33 in  two cases (27%) by in situ method, and three tumors were positive by PCR. HPV DNA was thought to be integrated based on punctate and combined punctate and diffuse signals. It is postulated that HPV integration leads to E2 disruption and loss of suppressive effects on E6 and E7, which are related to P53 and RB gene product.94

OTHER MALIGNANT NEOPLASMS

Neuroendocrine tumors of the cervix

Neuroendocrine tumors of the cervix consist of typical carcinoid tumor, atypical carcinoid, and small cell neuroendocrine carcinoma (Fig. 31). Typical carcinoid tumor is the least common neuroendocrine tumor in the cervix. Its histology resembles the typical carcinoid seen in other parts of the body. Atypical carcinoid tumor is the second least common and diagnosed by its features of mild to moderate cytological atypia with mitosis up to 10 per high power field. On the one end of poorly differentiated carcinoid tumors are small cell neuroendocrine carcinoma, which are the most common tumors in the cervix. Small cell neuroendocrine carcinoma are indistinguishable from small cell anaplastic carcinoma of the lung. Occasionally, squamous carcinoma and adenocarcinoma coexist with neuroendocrine carcinoma. Differential diagnosis of neuroendocrine tumors in the cervix partly relies on the immunoreactivity for neuroendocrine markers which include synaptophysin, neuron-specific enolase (NSE), chromogranin, and CD56. The prognosis of this group of tumors is related to the extent of disease and the degree of differentiation. Poorly differentiated tumors are highly aggressive with a propensity for local and distal spread.95, 96 A recent study of 31 neuroendocrine tumors of the cervix shows that the mean survival time for all patients was 32.3 months. The 2-year and 5-year survival rates were 54.8% and 31.5% for all patients. 97

 Fig. 31. Neuroendocrine tumors of the cervix. (A) Typical carcinoid shows glandular and trabecular growth patterns with minimal cytological atypia and rare mitosis. (B) Atypical carcinoid tumor has glandular and trabecular growth patterns with moderate cytological atypia and increased mitoses. (C) Small cell neuroendocrine carcinoma has sheets and trabecular growth patterns. Tumor cells are small oval and spindle with scant cytoplasm and hyperchromatic nuclei. Mitosis and apoptosis are numerous. (Hematoxylin-eosin stain, yellow and red bars: original magnification.)

 

Other malignant Mullerian tumors of the cervix

Some rare malignancies of Mullerian origin can develop in the uterine cervix as well. These include carcinosarcoma (malignant mixed Mullerian tumor) (Fig. 32), leiomyosarcoma (Fig. 33), adenosarcoma (Fig. 34), and Mullerian stromal sarcoma (Fig. 35). All these tumors show similar histology as seen in their counterparts of uterus, Fallopian tubes, and ovaries. Overall, carcinosarcoma and leiomyosarcoma behave more aggressively than adenosarcoma and stromal sarcoma. Recognition of these rare entities is valuable for early detection and appropriate clinical management.

Carcinosarcomas (malignant Müllerian mixed tumors, MMMT) of the uterine cervix are rare neoplasms. It seems that the epithelial differentiation of carcinosarcoma in the cervix is different from its counterparts of uterus and ovaries. Grayson and colleagues98, reported eight cases of carcinosarcoma in the cervix. Patients' ages ranged from 32 to 93 years. Seven cases showed in situ squamous cell carcinoma (SCC). The invasive epithelial component was composed of combined adenoid basal carcinoma, basaloid SCC, and adenoid cystic carcinoma in two cases. Keratinizing SCC, large cell nonkeratinizing SCC, undifferentiated carcinoma, and basaloid SCC predominated in the remaining tumors, one of which had admixed adenocystic carcinoma. The sarcomatous component was homologous and spindled with admixed myxoid areas in three lesions. Five tumors had a vimentin-positive epithelial component. Polymerase chain reaction detected HPV DNA in all eight cases. In situ hybridization probes to HPV types 6, 11, 16, 18, 31, and 33 demonstrated integrated HPV 16 in three cases. We have a collection of two cases with carcinosarcoma in the cervix. Both cases show mixed epithelial components of typical squamous cell carcinoma, adenoid basal, and adenoid cystic carcinoma along with undifferentiated sarcoma (Fig. 32).

 Fig. 32. Malignant mixed Mullerian tumor (carcinosarcoma) of the cervix. Tumor is biphasic. Epithelial component consists of squamous cell carcinoma, adenoid basal, and adenoid cystic carcinoma (AC). Stromal component is mainly less differentiated sarcoma (C). (Hematoxylin-eosin stain, red bars: original magnification.)    

 

 

 

 

Fig. 33. Leiomyosarcoma of the cervix. This leiomyosarcoma from the cervix is composed of epithelioid tumor cells with atypical and pleomorphic nuclei. Overlined cells are normal endocervical epithelium. (Hematoxylin-eosin stain, yellow bar: original magnification.)

 

 

 

 

 

>
 
   

Fig. 34. Mullerian adenosarcoma of the cervix.  Tumor consists of large and branching benign glandular epithelium surrounded by cellular atypical stromal cells (cuffing appearance). Stromal cells have moderate cytological atypia with mitoses up to five per 10 high power field. Focally overlined normal endocervical epithelium can be seen at upper part. (Hematoxylin-eosin stain, red bar: original magnification.)

 

 

 

Fig. 35. Mullerian stromal sarcoma of the cervix. The tumor consists of small and uniform endometrial stromal cells infiltrating into endocervix (left upper) and ectocervix (left lower). Tumor cells have an increased Ki-67 index (about 20% of tumor cells, right upper) and are immunoreactive for CD10 (right lower). (Hematoxylin-eosin stain, yellow bars: original magnification.)

 

 

 

 

 

 

 

 

Miscellaneous nonepithelial neoplasms

Other less common malignant neoplasms include aggressive angiomyxoma (Fig. 36), lymphoma (Fig. 37), leukemia, malignant melanoma, choriocarcinoma (Fig. 38), yolk sac tumor, Wilms' tumor, and others. These are detailed elsewhere.5, 99

Fig. 36. Aggresive angiomyxoma involving the cervix. Tumor is composed of mainly bland spindle and oval cells within a myxoid matrix. Thick and thin-walled vessels with hyalined changes are present. Tumor has an infiltrating growth pattern into the cervix. (Hematoxylin-eosin stain, yellow bars: original magnification.)

 

 

 

Fig. 37. Large B cell lymphoma of the cervix. This cervical biopsy is completely replaced by malignant lymphocytes with extensive tumor necrosis. Diagnosis is confirmed by immunostains (not shown). (Hematoxylin-eosin stain, yellow bars: original magnification.)

 

 

 

 Fig. 38. Chriocarcinoma involving the cervix. Tumor consists of a sheet of cytotrophoblaststic cells with areas of hemorrhage and scatterd syncytiotrophoblastic cells. Cytotrophoblastic cells are medium-sized polygonal and round cells with amphophilic cytoplsm. A normal endocervical gland is on the right side. (Hematoxylin-eosin stain, yellow bars: original magnification.)

 

 

 

 

 

Metastatic secondary tumors

Finally, secondary metastatic tumors to the uterine cervix occur most commonly from direct extension of adjacent malignancy, such as endometrium and vagina.5, 99 Less commonly, tumor of the breast (Fig. 39), ovary, colon, and stomach spread to the cervix by embolic phenomenon.5, 99

 

Fig. 39. Metastatic breast carcinoma in the cervix. (A) Metastatic ductal carcinoma in endocervix represented by multiple tumor nests in stroma and lymphovascular spaces. (B) Metastatic lobular carcinoma shows infiltrating cores and individual cells in cervical stroma. (Hematoxylin-eosin stain, yellow and red bars: original magnification.)    

 

 

 

 

PROGNOSTIC FACTORS

In recent years several large series have applied statistical models to identify important prognostic parameters of cervical carcinoma among women treated by radical surgery and radiation therapy. In the study of Sevin and associates,100 370 women with stage I or II carcinoma were treated by radical hysterectomy and pelvic lymphadenectomy. By univariate analysis, the disease free survival rates were closely related to the depth of stromal invasion, tumor size, presence or absence of lymphatic vascular space invasion, pelvic lymph node status, tumor volume, and clinical stage.100

Kamura and colleagues101 studied 211 women with stage IB and II cervical carcinoma treated by radical hysterectomy and pelvic lymphadenectomy. By univariate analysis, 5-year survival rates were correlated to the lymph node status; cell type (squamous carcinoma vs adenocarcinoma); tumor dimension; depth of cervical wall invasion measured in millimeters and expressed by inner third, middle third, and outer third; lymphatic vascular space invasion; and parametrial invasion. The histologic grade was not evaluated in this study.101

Fuller and colleagues102 studied 431 women with stage IB or IIA carcinoma treated by radical hysterectomy, including 85% squamous carcinomas, 9% adenocarcinomas, 3% adenosquamous carcinomas, 2% small cell carcinomas, and 1% clear cell carcinomas. A decreased survival was strongly related to the presence of pelvic lymph node metastasis.102 Among lymph node negative cases, adenocarcinoma cell type, increasing tumor size, deeper stromal invasion, and poor histologic grade were associated with decreased survival.102 Increasing tumor size and depth of invasion, and histologic grade were covariable and predictors of both lymph node metastasis and recurrence.102 In this study, poorly differentiated tumors had larger tumor size.102

Thus most authors have agreed that for surgically treated stage IB and II cervical carcinomas, the depth of stromal invasion, tumor dimension, the presence or absence of lymphatic vascular space invasion, and pelvic lymph node status are important prognosticators. The value of classification by cell type and histologic grade continues to be controversial.

By a multivariate stepwise regression model, it is possible to use several parameters to subdivide tumors into different risk groups. Kamura and associates101 developed such a scheme based on lymph node status, cell type, and tumor dimension. Sevin and colleagues100 identified three risk groups using depth of stromal invasion, lymphatic vascular space invasion, age, and lymph node status.

When treated by radiation therapy, somewhat different prognostic factors are identified. Barillot and colleagues103 reviewed 1875 women with cervical carcinoma treated by radiation therapy, including stage IA/IB (25.5%), IIA (12%), IIb (29%), IIIA (5%), IIIB (25%), and IV (3.5%). By univariate analysis of stage I/II cases: FIGO stage, tumor diameter, and lymph nodal status were significant parameters. The 5-year survival rates were 83.5% for stage IB, 81% for stage IIA, 71% for stage IIB, 65% for stage IIIA, and 59% for stage IIIB.103 For tumors smaller than 3 cm the 5-year survival rates were 86%, for those with 3–5-cm tumors the 5-year survival rates were 76%, and for those with tumors larger than 5 cm the 5-year survival rates were 61.5%. In the case of negative lymphangiogram the survival rates were 90%, compared with 65% if positive. Women younger than 30 years had a better survival rates than older women (91% vs 75%). Women with adenocarcinoma had 10% lower 5-year survival rates than those with squamous cell carcinoma.103

By multivariate analysis, FIGO stage and nodal involvement remained significant for all stages. For stage I/II tumors, tumor larger than 5 cm and adenocarcinoma were poor prognosticators.103

Cell type

The differences in prognosis of women with cervical squamous carcinoma, adenocarcinoma, and adenosquamous carcinoma have been controversial for sometime. Some investigators have found no difference in survival for the three tumor types when compared stage by stage.104 In a study by Yazigi and associates,105 women with stage IB adenosquamous carcinoma 3 cm or smaller in size had similar rates for pelvic nodal metastasis and 5-year survival to women with comparable squamous carcinomas. Others have noted worse survival for women with adenocarcinoma and adenosquamous carcinoma compared with squamous carcinoma101, 106 (Table 7).

Table 7. Five-year survival rates in surgically treated cases

Parameter

Kamura et al.101

Sevin et al.100

No. of cases

211 IB and II

370 I and II

Cell type

Squamous carcinoma 91.1%

Not significant

 

Adenocarcinoma 70.1%

 

Tumor size

<2 cm 97.6%

<1 cm 93%

 

2–4 cm 85.6%

1.1–2.0 cm 76%

 

>4 cm 80.1%

2.1–3.0 cm 64%

Stromal invasion

<3 mm 95.7%

 
 

3–5 mm 91.7%

 

5–10 mm 83%

 

>10 mm 81.8%

 

<1/3 94.8%

 

Middle third 88.1%

 

>2/3 79.9%

Lymphatic vascular space invasion

Absent 91.5%

Absent 85%

 

Present 82.4%

Present 62%

Parametrial disease

Absent 90.3%

 
 

Present 77.3%

Lymph node metastasis

Negative 90.8%

Negative 77%

 

1+ 96.7%

1–2+ 55%

 

2+ 44.3%

>2+ 39%

 

3+ 36%

 

Histologic grade

Not evaluated

Not significant


The data collected from the Patient Care and Evaluation Study on Cancer (PCE) of American College of Surgeons from 1984 to 1990 were complex.4 Women with squamous carcinoma had higher survival rates than those with adenocarcinoma for all stages, but statistically significant only for stage II cases. For stage IB tumors, patients with squamous carcinoma and adenocarcinoma treated by surgery had better survival (93.1% and 94.6%, respectively) than radiation alone or combined surgery and radiation.4 In contrast, in women with adenosquamous carcinoma the 5-year survival rates were 87.3% following combined therapy, 69.2% by surgery alone, and 79.2% by radiation therapy alone.4

In the study of Costa and associates,79 which included 35 pure adenocarcinoma, 26 adenosquamous carcinoma (four glassy cell carcinoma), and four villoglandular papillary adenocarcinoma, 21 (38%) patients had recurrence (three local, 10 distant, and eight both). Thirty-five (62%) women were disease free. Adenosquamous and serous differentiation were the only histological types in which women developed tumor recurrence.79 Other risk factors for recurrence included vascular space invasion, deeper invasion, high nuclear grade, large tumor on clinical or pathologic examination, and lymph node metastasis at surgery. There was no difference in prognosis among mucinous, endometrioid or clear cell tumors. All patients with villoglandular adenocarcinoma were alive and well.79

As for glassy cell carcinoma, studies have shown a high frequency of pelvic and extrapelvic spread, poor response to surgery and/or radiotherapy, and 5-year survival rates in the range of 31–33%.107 This poor outcome is thought in part to be related to radioresistance and understaging of the tumor.107

Degree of differentiation

The histologic grade of stage I and II cervical carcinomas (including squamous carcinoma and adenocarcinoma) did not affect survival rates in the study by Sevin and associates.100 Others have found poorly differentiated tumor to have a higher  rate of pelvic nodal metastases.102, 108 The degree of differentiation in adenocarcinoma is closely related to prognosis and pelvic nodal metastasis. In stage I and II adenocarcinomas, pelvic nodal metastases were found in 5% of grade I, 11% of grade II, and 50% of grade III tumors.62

Tumor dimension and depth of stromal invasion

Careful assessment of tumor dimension by clinical or pathologic method provides useful prognostic information (Table 7). The depth of stromal invasion adds critical information about the survival rates and the risk for pelvic nodal metastasis and tumor recurrence (Table 7). The depth of stromal invasion is measured from the basement membrane of the overlying abnormal epithelium to the deepest tumor and expressed in millimeters. In ulcerated tumor, the adjacent intact mucosal base is used as a reference point for invasion. Stromal invasion is also expressed by dividing the cervical wall into thirds. In a study of stages IB, IIA, or IIB squamous carcinomas, pelvic lymph node metastasis was found in none of 62 tumors involving the inner one third, in 16 of 130 (12%) tumors invading up to the middle third, and 55 of 226 (24%) tumors extending into outer one third.102

Looked at from a different perspective, Kishi and colleagues109 measured the thickness of uninvolved cervical stroma from the deepest tumor to the external cervical wall in 287 stage IB, IIA, or IIB cervical squamous cancers. The pelvic nodal metastatic and 5-year cancer death rates were 7% and 8%, respectively, when the uninvolved stroma measured greater than 3 mm. Corresponding figures were 37% and 26% when the uninvolved stroma measured less than 3 mm. The authors feel that the uninvolved stroma acts as a barrier to cancer spread, and its width is therefore a more important measurement than the depth of tumor invasion.109

Parametrial spread carries important prognostic information. Its presence or absence should be noted in all pathology reports. In surgically treated stage IB and II cervical cancers, the 5-year survival rates were 90.3% and 77.3% without and with parametrial involvement, respectively101 (Table 7). Tumor extension to this highly vascular site occurs by contiguous spread, and less often from lymphatic invasion (Fig. 40). When present, parametrial invasion is associated with a higher incidence of vascular invasion (Fig. 40), positive lymph nodes, recurrence, and death.108, 110

Fig. 40. (A) Tumor extension into the parametrial fibroadipose tissue (left field). The deepest cervical stroma reveals smooth muscle tissue and blood vessels (right field). (B) Venous invasion in the parametrial tissue. The artery in the center of the slide is not invaded by tumor. (Hematoxylin-eosin stain, original magnification A: x40, B: x100.)





Lymphatic vascular space invasion

Shrinkage artifact after formalin fixation often results in clear empty spaces in the periphery of tumor nests simulating vascular space. These artifacts do not have well-defined endothelial cells (Fig. 41). In true vascular invasion, the tumor cells are partially adherent to the endothelial cells, which should be clearly identifiable (Fig. 41). In addition, blood and sometimes fibrin thrombi are present in the vascular lumen. The frequency of lymphatic vascular space invasion is closely related to the depth of stromal invasion.111 Vascular invasion is associated with increased pelvic nodal metastasis, higher tumor recurrence, and decreased survival in stage I and II squamous carcinoma and adenocarcinoma101, 102, 108, 111, 112 (Table 5).

Fig. 41. Vascular lymphatic space invasion. (A) Shrinkage artifact around the tumor nests simulates vascular lymphatic space invasion. (B) True vascular lymphatic space should demonstrate clearly identifiable endothelial cells. The malignant squamous cells are partially adherent to the vessel wall. (Hematoxylin-eosin stain, original magnification A: x200, B: x400.) 

 

 

 

Some studies have reported a significant difference between lymphatic and blood vessel invasion in stage I disease. In women treated with surgery alone (hysterectomy and pelvic lymphadenectomy) 5-year survival was 69% in the presence of lymphatic invasion, compared with 30% in women with blood vessel invasion.113 Pelvic lymph node metastasis is higher when there is blood vessel invasion.102

This dramatic association between vascular invasion and disease recurrence has not been observed in later stages. In fact, several studies of stage II and III cervical squamous carcinomas found that vascular invasion had no bearing on long-term survival.114

Growth patterns and stromal response

A variety of growth patterns and stromal reactions have been described in cervical squamous cell carcinoma, but none are prognostically useful. Similarly, the results of vascular density counts are conflicting in relation to radiosensitivity of the tumor and prognosis.

Lymph node metastasis

The frequency of pelvic lymph node metastasis is influenced by such parameters as FIGO stage, tumor size, depth of invasion, lymphatic vascular space invasion, and histologic grade.102, 108, 115, 116, 117. In some series, 15% of clinical stage I and 26–35% of stage II cervical carcinomas have positive lymph nodes at the time of diagnosis.102, 118, 119 The nodal groups most frequently involved are the paracervical, obturator and external iliac lymph node chains (Fig. 42).120 The likelihood of recurrence and death is increased in the presence of pelvic lymph node metastases and is related to the number of positive nodes.116, 117 In a series of 97 patients with stage IB/IIB carcinoma, one third of patients with one positive lymph node and two thirds with three or more positive nodes had recurrence of tumor within 5 years.121 In another study of stage I and II carcinomas, the rate of survival was 59% with unilateral and 20% with bilateral lymph node metastases.117

Fig. 42. Metastatic squmamous cell carcinoma in iliac lymph node. Section shows a close view of clusters of malignant squamous cells in side of iliac lymph node. (Hematoxylin-eosin stain, yellow bars: original magnification.)  

 

 

 

 

 


From the iliac lymph nodes tumor may spread to involve paraaortic nodes, and, from there, the scalene nodes. Tumor involvement of these sites is associated with disseminated disease in more than 75% of patients.122 Paraaortic lymph node involvement is present in 6% of stage IB carcinoma and 30% of stage II and III disease.123, 124 When all series are combined, the overall incidence of scalene lymph node metastasis from cervical carcinoma is 15%.125 When paraaortic lymph nodes are involved, the frequency of an occult scalene metastasis ranges from 0% to 50% (mean 28%).125 Identification of such patients through scalene biopsy specimens may result in more accurate staging.

In women with stage I or II cervical adenocarcinoma treated surgically, lymph node metastases in the pelvic or paraaortic region occurred in 15% of stage I, and 40% of stage II tumors. In the presence of pelvic lymph node metastasis, the 5-year survival rate decreased from 92% to 10%.62

TUMOR RECURRENCE

Multiple histopathologic factors influence the likelihood of tumor recurrence and survival. These include clinical stage, tumor size, depth of invasion, stromal response, presence of vascular invasion, parametrial extension, lymph node involvement, S-phase rate, and immune status.

Tumor recurrences are divided into three categories: central (involving vaginal cuff, bladder, or rectum), pelvic sidewall, and distant or extrapelvic. In multiple studies combined, tumor recurrence is reported to be central in 14–28%, sidewall or sidewall and central in 37–59%, and distant in 35–42% of cases.126, 127, 128 In a large study, 40 of 303 (13%) women with stage IB/IIB cervical cancers developed recurrence following radical hysterectomy and pelvic lymphadenectomy.126 In a literature review, tumor recurrence occurs within 12 months of initial treatment in 45–58% of cases, and within 3 years in 70–90% of cases.126 Pelvic recurrence may be asymptomatic and detected only on physical examination, or may be suspected by nonspecific symptoms such as vaginal bleeding or discharge. Pelvic sidewall recurrence may produce pain in the lower abdomen, back, hip, or leg. Distant metastases may present with pain or a mass lesion.

Usual sites of distant metastasis in cervical carcinoma include periureteral, abdominal, hepatic, and paraaortic regions. Spread to scalene node occurs via thoracic duct. Unusual sites of recurrence, such as cutaneous lymphatic dissemination, are occasionally reported.129

Survival statistics following tumor recurrence are discouraging. In one study, 36% of women with central recurrence died within 1 year, compared with 65% with sidewall or distant metastases. Only 13% of patients had no evidence of disease 5 years following tumor recurrence.126

Successful treatment of pelvic recurrences by radiation therapy has been reported. In a study by Larson and colleagues,127 eight of 15 (53%) patients with pelvic recurrence treated with irradiation were free of disease 10–126 months (median 48 months) after recurrence. In a literature review, 80% of patients with recurrent disease failed to be controlled.126

Autopsy studies reveal that the cause of death in cervical cancer has changed over the years. Although the incidence of ureteral blockage has remained unchanged, subsequent death from uremia has decreased in incidence from 28% between the years 1935 and 1964, to 6.7% in the years 1965–1979. This difference is attributed to the benefits of radiotherapy. The most frequent terminal events are pulmonary embolus, myocardial infarct, bronchopneumonia, and cachexia.130

STUDIES USING SPECIAL TECHNIQUES

A variety of tumor antigens have been identified in cervical carcinoma using immunohistochemical techniques on tissue sections. Those with possible clinical utility are discussed here. CEA is found in both squamous and adenocarcinoma, as well as in normal cervical epithelium.131 In a series of 241 patients, 63% of large cell nonkeratinizing squamous carcinomas, 78% of keratinizing squamous carcinomas, 67% of small cell carcinomas, and 36% of adenocarcinomas were positive for CEA.132 The diagnostic utility of this antigen is limited, however, as it is found in benign, dysplastic, and malignant conditions. In addition, the presence of CEA in malignant tissue sections by itself has no prognostic significance.132, 133

In the study of Borras and associates,134 serum tumor antigens were determined by immunoradiometric assay in 96 women with invasive carcinoma. Elevated levels of serum CEA, CA 19.9, and CA 125 were found in 33%, 32%, and 21.5% of cases, respectively. Increased CEA and CA 19.9 were related to clinical stage. Serum CA 12.5 and CA 19.9 were higher in patients with adenocarcinoma than squamous carcinoma. When disease free, these antigens tended to decrease. All progressive cases had an elevated level in one of these antigens.134 Thus, these tumor markers are useful for monitoring tumor recurrence, especially for adenocarcinoma.

Squamous cell carcinoma (SCC) antigen is one of 14 subfractions of the TA-4 tumor antigen, isolated in 1977 from cervical squamous carcinoma by Kato and Torigoe.135 Like CEA, SCC antigen can be demonstrated in both benign and malignant cervical epithelium, and increased serum levels occur almost exclusively in cancer patients.136 In a study of 96 cervical carcinoma patients who had increased serum levels of SCC antigen at the time of diagnosis, persistently high levels following completion of radiotherapy were significantly associated with biopsy-proven residual disease. In 60% of patients with persistently high SCC antigen levels, residual tumor was found on cervical biopsy.137

The role of oncogenes in cervical carcinoma has also been investigated. Mutations and overexpression of both the c-myc and ras oncogene have been demonstrated in cervical carcinoma.138, 139, 140, 141 Some studies have correlated the degree of abnormal expression with prognosis. In one study, expression of the c-myc oncogene was increased in 25 of 72 stage I and II cervical carcinomas, and was associated with an eightfold or higher increase in the rate of early relapse in these patients.141

Mandai and associates142 used immunohistochemical stains for the expression of nm23-H1 and c-erb-2 proteins. nm23-H1 gene was originally cloned from the murine melanoma cell lines with low and high metastatic potential. It was identified later in the human genes. nm23-H1 expression is associated with better prognosis and lower lymph node metastasis in breast ductal carcinoma, hepatocellular carcinoma, and gastric carcinoma patients.142 c-erb-2, a member of epidermal growth factor receptor family, when overexpressed, is associated with poor prognosis in breast carcinoma. nm23-H1 was expressed in 46% of cervical adenocarcinomas and 36% of squamous carcinomas.142 c-erb-2 was overexpressed in 49% of cervical adenocarcinoma and 38% of squamous carcinomas. A negative nm23-HI and an overexpressed c-erb-2 were associated with increased lymph node metastasis and poor prognosis in adenocarcinoma. These findings were not applicable to squamous carcinoma.142

Estrogen and progesterone receptors have been detected in both benign and malignant cervical epithelia.143, 144 While the techniques used to detect these receptors vary among studies, most investigators have found no prognostic significance of the level of estrogen or progesterone receptors in cervical squamous carcinoma. In a study of 70 cases, Hunter and colleagues143 found no significant correlation between steroid receptors and a variety of parameters, including stage, menopausal status, cell type, histologic grade or survival.

Flow cytometric analysis of cervical squamous carcinoma has been carried out by numerous investigators. In his review of the literature, Strang145 summarized the data on DNA ploidy and S-phase rate. Aneuploidy was found in the majority of cervical tumors, with only 20–40% of cases studied being peridiploid. A higher proportion of tumors with aneuploidy and high S-phase rates were found in stages III and IV cancers compared with lower-stage tumors, possibly reflecting successive changes in karyotype with tumor progression. Increasing age and postmenopausal status were also associated with aneuploidy and high S-phase rates (p <0.01).145 Correlations were found between aneuploidy and aggressive histopathologic features, such as infiltrative growth pattern, vascular invasion, and sparse lymphoplasmacytic infiltrate.145

Concerning the prognostic significance of DNA ploidy in cervical squamous cell carcinoma, the results have been conflicting. When the reports are critically evaluated, it appears that the prognosis for diploid and aneuploid tumors is similar. This may be due to the fact that aneuploid tumors are more radiosensitive than diploid tumors. High S-phase rates, on the other hand, were correlated with early recurrence and decreased survival in many studies. In a study of 133 patients, 17 of 81 (21%) of cervical tumors with an S-phase rate of less than 20% presented with early relapses, compared with 25 of 52 (48%) tumors with S-phase rates more than 20% (p <0.01).146

Connor and associates147 studied 53 IB cervical carcinomas by flow cytometry. Of these, 25 (47%) tumors were aneuploid with a mean DNA index of 1.52% ± 0.4%. The mean S-phase was 7.6% ± 0.4% for diploid tumors and 9.2% ± 0.4% for aneuploid neoplasms. Only the depth of stromal invasion was correlated with recurrence or survival following radical hysterectomy and pelvic lymphadenectomy. DNA index and S-phase cells did not correlate with recurrence or survival.147 A similar finding was reported for stage I/IIA cervical carcinomas.148

CONCLUSION

Optimal management of cervical cancer patients requires accurate assessment of the quality and the quantity of the neoplasm. Proper handling of the surgical specimens allows for comprehensive reporting of prognostically important pathologic findings. The use of immunohistochemistry and other techniques further enhances the validity of diagnosis and prognosis.

REFERENCES

1

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics, 2008. CA Cancer J Clin. 58:71, 2008

 

2

Leminen A, Paavonen J, Forss M et al: Adenocarcinoma of the uterine cervix. Cancer 65: 53, 1990

 

3

Mayer EG, Galindo J, Davis J et al: Adenocarcinoma of the uterine cervix: Incidence and the role of radiation therapy. Radiology 121: 725, 1976

 

4

Shingleton HM, Bell MC, Fremgen A et al: Is there really a difference in survival of women with squamous cell carcinoma, adenocarcinoma, and adenosquamous cell carcinoma of the cervix? Cancer 76: 1948, 1995

 

5

Fu YS, Reagan JW: Pathology of the Uterine Cervix, Vagina, and Vulva. Philadelphia, WB Saunders, 1989

 

6

Montz FJ, Holschneider CH, Thompson LDR: Large-loop excision of the transformation zone: Effect on the pathologic interpretation of resection margins. Obstet Gynecol 81: 976, 1993

 

7

Felix JC, Muderspach LI, Duggan BD, Roman LD: The significance of positive margins in loop electrosurgical cone biopsies. Obstet Gynecol 84: 996, 1994

 

8

Lorincz A, Reid R, Jenson AB et al: Human papillomavirus infection of the cervix: relative risk associations of fifteen common anogenital types. Obstet Gynecol 79: 328, 1992

 

9

Creasman WT.New gynecologic cancer staging. Gynecol Oncol. 1995 Aug;58(2):157-8.

 PubMed

10

Pecorelli S, Zigliani L, Odicino F. Revised FIGO staging for carcinoma of the cervix. Int J Gynaecol Obstet. 2009 May;105(2):107-8.

 PubMed

11

D.D. Davey, M.H. Neal, D.C. Wilbur, T.J. Colgan, P.E. Styer and D.R. Mody, Bethesda 2001 implementation and reporting rates: 2003 practices of participants in the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology, Arch Pathol Lab Med 128 (2004), pp. 1224–1229.

 

12

Clifford GM, Rana RK, Franceschi S et al: Human papillomavirus genotype distribution in low-grade cervical lesions:comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1157-64.

 PubMed

13

Schlecht NF, Kulaga S, Robitaille J et al: Persistent human papillomavirus infection as a predictor of cervicalintraepithelial neoplasia. JAMA. 2001 Dec 26;286(24):3106-14.

 PubMed

14

Hasumi K, Ehrmann RL: Clear cell carcinoma of the uterine endocervix with an in situ component. Cancer 42: 2435, 1978

 

15

Kwong RA, Nguyen TV, Bova RJ et al: Overexpression of E2F-1 is associated with increased disease-free survival insquamous cell carcinoma of the anterior tongue. Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3705-11.

 PubMed

16

Clifford GM, Smith JS, Aguado T et al: Comparison of HPV type distribution in high-grade cervical lesions and cervical Br J Cancer. 2003 Jul 7;89(1):101-5.

 PubMed

17

Nasu I, Meurer W, Fu YS: Endocervical glandular atypia and adenocarcinoma: A correlation of cytology and histology. Int J Gynecol Pathol 12: 208, 1993

 

18

James MC, Peters G. Alternative product of the p16/CKDN2A locus connects the Rb and p53 tumor suppressors. Prog Cell Cycle Res. 4:71, 2000

 

19

Tsoumpou I, Arbyn M, Kyrgiou M, Wentzensen N, Koliopoulos G, Martin-Hirsch P, Malamou-Mitsi V, Paraskevaidis E. p16(INK4a) immunostaining in cytological and histological specimens from the uterine cervix: a systematic review and meta-analysis. Cancer Treat Rev. 35:210, 2009

 

20

Hopkins MP, Morley GW: Microinvasive squamous cell carcinoma of the cervix. J Reprod Med. 1994 Sep;39(9):671-3.

 PubMed

21

Wentz WB, Reagan JW: Survival in cervical cancer with respect to cell type. Cancer 12: 384, 1959

 

22

Albores-Saavedra J, Gersell D, Gilks CB et al: Terminology of endocrine tumors of the uterine cervix: results of a workshop sponsored by the College of American Pathologists and the National Cancer Institute. Arch Pathol Lab Med 121: 34, 1997

 

23

Reagan JW, Ng ABP: The cellular manifestations of uterine carcinogenesis. In Norris NJ, Hertig AT, Abel MR (eds): The Uterus, p 320. Baltimore, Williams and Wilkins, 1973

 

24

Fu YS, Ko JH: Histopathology of preinvasive and invasive squamous neoplasia. In Rubin SC, Hoskins WJ (eds): Cervical Cancer and Preinvasive Neoplasia, pp 77–92. Philadelphia, Lippincott-Raven Publishers, 1996

 

25

Groben P, Reddick R, Askin F: The pathologic spectrum of small cell carcinoma of the cervix. Int J Gynecol Pathol 4: 42, 1985

 

26

Walker AN, Mills SE, Taylor PT: Cervical neuroendocrine carcinoma: A clinical and light microscopic study of 14 cases. Int J Gynecol Pathol 7: 64, 1988

 

27

Gersell DJ, Mazoujian G, Mutch DG et al: Small-cell undifferentiated carcinoma of the cervix: a clinicopathologic, ultrastructural, and immunocytochemical study of 15 cases. Am J Surg Pathol 12: 684, 1988

 

28

Silva EG, Brock WA, Gershenson D et al: Small cell carcinoma of the uterine cervix: Pathology and prognostic factors. Surg Pathol 2: 105, 1989

 

29

Clement PB: Miscellaneous primary tumors and metastatic tumors of the uterine cervix. Semin Diag Pathol 7: 228, 1990

 

30

Fetissof F, Serres G, Arbeille B, de Muret A, Sam-Giao M, Lansac J. Argyrophilic cells and ectocervical epithelium. Int J Gynecol Pathol 10:177, 1991

 

31

Ambros RA, Park JS, Shah KV, Kurman RJ. Evaluation of histologic, morphometric, and immunohistochemical criteria in the differential diagnosis of small cell carcinomas of the cervix with particular reference to human papillomavirus types 16 and 18. Mod Pathol 4:586, 1991

 

32

Stoler MH, Mills SE, Gersell DJ, Walker AN. Small-cell neuroendocrine carcinoma of the cervix: A human papillomavirus type 18-associated cancer. Am J Surg Pathol 15: 28, 1991

 

33

Abeler VM, Holm R, Nesland JM, Kjorstad KE. Small cell carcinoma of the cervix: A clinicopathologic study of 26 patients. Cancer 73: 672, 1994

 

34

Gloor E, Ruzicka J: Morphology of adenocarcinoma in situ of the uterine cervix: A study of 14 cases. Cancer 49: 294, 1982

 

35

Sevin SU, Method MW, Nadji M, Lu Y, Averette HA: Efficacy of radical hysterectomy as treatment for patients with small cell carcinoma of the cervix. Cancer 77: 1489, 1996

 

36

Zaino RJ, Ward S, Delgado G et al. Histopathologic predictors of the behavior of surgically treated stage IB squamous cell carcinoma of the cervix: a gynecologic oncology group study. Cancer 69: 1750, 1992

 

37

. Delgado G, Bundy BN, Fowler WC et al: A prospective surgical pathological study of stage I squamous carcinoma of the cervix: A Gynecologic Oncologic Group study. Gynecol Oncol 35: 314, 1989

 

38

Stock RJ, Zaino R, Bundy BN et al.Evaluation and comparison of histopathologic grading systems of epithelial carcinoma of the uterine cervix: Gynecologic Oncology Group studies. Int J Gynecol Pathol 13: 99, 1994

 

39

Fuller AF, Elliott N, Kosloff C et al: Determinants of increased risk for recurrence in patients undergoing radical hysterectomy for stage IB and IIA carcinoma of the cervix. Gynecol Oncol 33: 34, 1989

 

40

Reagan JW, Fu YS: Histologic types and prognosis of cancers of the uterine cervix. Int J Radiat Oncol Biol Phys 5: 1015, 1979

 

41

Crissman JD, Budhraja M, Aron BS et al: Histopatholgic prognostic factors in stage II and III squamous cell carcinoma of the uterine cervix. Int J Gynecol Pathol 6: 97, 1987

 

42

Stendahl U, Willen H, Willen R. Classification and grading of invasive squamous cell carcinoma of the uterine cervix. Acta Radiol Oncol 18:481, 1979

 

43

Tiltman AJ, Atad J: Verrucous carcinoma of the cervix with endometrial involvement. Int J Gynecol Pathol 1: 221, 1982

 

44

Koenig C, Turnicky RP, Kankam CF, Tavassoli FA: Papillary squamotransitional cell carcinoma of the cervix: A report of 32 cases. Am J Surg Pathol 21: 915, 1997

 

45

Albores-Saavedra J, Young RH: Transitional cell neoplasms (carcinomas and inverted papillomas) of the uterine cervix: A report of five cases. Am J Surg Pathol 19: 1138, 1995

 

46

Randall ME, Andersen WA, Mills SE et al: Papillary squamous cell carcinoma of the uterine cervix: a clinicopathologic study of nine cases. Int J Gynecol Pathol 5: 1, 1986

 

47

Hasumi D, Sugano H, Sakamoto G et al: Circumscribed carcinoma of the uterine cervix, with marked lymphocytic infiltration. Cancer 39: 2503, 1977

 

48

Mills SE, Austin MB, Randall ME: Lymphoepithelioma-like carcinoma of the uterine cervix. Am J Surg Pathol 9: 883, 1985

 

49

Halpin TF, Hunter RE, Cohen MB: Lymphoepithelioma of the uterine cervix. Gynecol Oncol 34: 101, 1989

 

50

Tseng CJ, Pao CC, Tseng LH et al: Lymphoepithelioma-like carcinoma of the uterine cervix: association with Epstein-Barr virus and human papillomavirus. Cancer 80: 91, 1997

 

51

Steeper TA, Piscioli F, Rosai J: Squamous cell carcinoma with sarcoma-like stroma of the female genital tract: Clinicopathologic study of four cases. Cancer 52: 890, 1983

 

52

Watty EI, Johnston LW, Bainborough AR: Polypoid carcinoma of the uterine cervix simulating “pseudosarcoma” and “carcinosarcoma” of esophagus and upper respiratory tract. Diagn Gynecol Obstet 3: 205, 1981

 

53

Ioffe OB, Sagae S, Moritani S et al: Proposal of a new scoring scheme for the diagnosis of noninvasive endocervicalglandular lesions. Am J Surg Pathol. 2003 Apr;27(4):452-60.

 PubMed

54

Missaoui N, Hmissa S, Frappart L et al: p16INK4A overexpression and HPV infection in uterine cervix adenocarcinoma. Virchows Arch. 2006 May;448(5):597-603. Epub 2006 Feb 22.

 PubMed

55

Steiner G, Friedell GH: Adenosquamous carcinoma in situ of the cervix. Cancer 18: 807, 1965

 

56

Christopherson WM, Nealon N, Gray LA Sr: Noninvasive precursor lesions of adenocarcinoma and mixed adenosquamous carcinoma of the cervix uteri. Cancer 44: 975, 1979

 

57

Wolf JK, Levenback C, Malpica A, Morris M, Burke T, Michell MF: Adenocarcinoma in situ of the cervix: Significance of cone biopsy margins. Obstet Gynecol 88: 82, 1996

 

58

Ostor AG, Pagano R, Davoren RAM et al: Adenocarcinoma in situ of the cervix. Int J Gynecol Path 3: 179, 1984

 

59

Bertrand M, Lickrish GM, Colgan TJ: The anatomic distribution of cervical adenocarcinoma in situ: Implications for the treatment. Am J Obstet Gynecol 157: 21, 1987

 

60

Teshima S, Shimosato Y, Kishi K et al: Early stage adenocarcinoma of the uterine cervix. Histopathologic analysis with consideration of histogenesis. Cancer 56: 167, 1985

 

61

Buscema J, Woodruff JD: Significance of neoplastic atypicalities in endocervical epithelium. Gynecol Oncol 17: 356, 1984

 

62

Berek JS, Hacker NF, Fu YS et al: Adenocarcinoma of the uterine cervic: Histologic variables associated with lymph node metastasis and survival. Obstet Gynecol 65: 46, 1984

 

63

Ostor A, Rome R, Quinn M: Microinvasive adenocarcinoma of the cervix: A clinicopathologic study of 77 women. Obstet Gynecol 89: 88, 1997

 

64

Greer BE, Figge DC, Tamimi HK et al: Stage IB adenocarcinoma of the cervix treated by radical hysterectomy and pelvic lymph node dissection. Am J Obstet Gynecol 160: 1509, 1989

 

65

Fu YS, Reagan JW, Hsiu JG et al: Adenocarcinoma and mixed carcinoma of the uterine cervix: I. A clinicopathologic study. Cancer 49: 2560, 1982

 

66

McKelvey JL, Goodlin RR: Adenoma malignum of the cervix: A cancer of deceptively innocent histological pattern. Cancer 16: 549, 1963

 

67

Silverberg SG, Hurt WG: Minimal deviation adenocarcinoma (“adenoma malignum”) of the cervix. Am J Obstet Gynecol 121: 971, 1975

 

68

Kaminski PF, Norris HJ: Minimal deviation carcinoma (adenoma malignum) of the cervix. Int J Gynecol Pathol 2: 141, 1983

 

69

Kaku T, Enjoji M: Extremely well-differentiated adenocarcinoma ("adenoma malignum"). Int J Gynecol Pathol 2: 28, 1983

 

70

Michael H, Grawe L, Kraus FT: Minimal deviation endocervical adenocarcinoma: Clinical and histologic features, immunohistochemical staining for carcinoembryonic antigen, and differentiation from confusing benign lesions. Int J Gynecol Pathol 3: 261, 1984

 

71

Young RH, Scully RE: Villoglandular papillary adenocarcinoma of the uterine cervix: A clinicopathologic analysis of 13 cases. Cancer 63: 1773, 1989

 

72

Jones MW, Silverberg SG, Kurman RJ: Well-differentiated villoglandular adenocarcinoma of the uterine cervix: A clinicopathologic study of 24 cases. Int J Gynecol Pathol 12: 1, 1993

 

73

Cohen C, Shulman G, Budgeon LR: Endocervical and endometrial adenocarcinoma. An immunoperoxidase and histochemical study. Am J Surg Pathol 6: 151, 1982

 

74

Dabbs DJ, Geisinger KR, Norris HT: Intermediate filaments in endometrial and endocervical carcinomas: The diagnostic utility of vimentin patterns. Am J Surg Pathol 10: 568, 1986

 

75

Fawcett KJ, Dockerty MB, Hunt AB: Mesonephric carcinoma of the cervix uteri: A clinical and pathologic study. Am J Obstet Gynecol 95: 1068, 1966

 

76

Kaminski PF, Maier RC: Clear cell adenocarcinoma of the cervix unrelated to diethylstilbestrol exposure. Obstet Gynecol 62: 720, 1983

 

77

Herbst AL, Anderson D: Clear cell adenocarcinoma of the vagina and cervix secondary to intrauterine exposure to diethylstilbestrol. Semin Surg Oncol 6: 343, 1990

 

78

Young RH, Scully RE: Invasive adenocarcinoma and related tumors of the uterine cervix. Semin Diag Pathol 7: 205, 1990

 

79

Costa MJ, McIlnay KR, Trelford J: Cervical carcinoma with glandular differentiation: histological evaluation predicts disease recurrence in clinical stage I or II patients. Hum Pathol 26: 829, 1995

 

80

Glucksmann A, Cherry CP: Incidence, histology and response to radiation of mixed carcinomas (adenoacanthomas) of the uterine cervix. Cancer 9: 971, 1956

 

81

Ferry JA, Scully RE: Mesonephric remnants, hyperplasia and neoplasia in the uterine cervix: A study of 49 cases. Am J Surg Pathol 14: 1100, 1990

 

82

Clement PB, Young RH, Keh P, Ostor AG, Scully RE: Malignant mesonephric neoplasms of the uterine cervix. A report of eight cases, including four with a malignant spindle cell component. Am J Surg Pathol 19: 1158, 1995

 

83

Thelmo WL, Nicastri AD, Fruchter R et al: Mucoepidermoid carcinoma of uterine cervix stage IB: Long-term follow-up, histochemical and immunohistochemical study. Int J Gynecol Pathol 9: 316, 1990

 

84

Benda JA, Platz CE, Buchsbaum H et al: Mucin production in defining mixed carcinoma of the uterine cervix: A clinicopathologic study. Int J Gynecol Pathol 4: 314, 1985

 

85

Ireland D, Cole S, Kelly P et al: Mucin production in cervical intraepithelial neoplasia and in stage 1b carcinoma of cervix with pelvic lymph node metastases. Br J Obstet Gynaecol 94: 467, 1987

 

86

Maier RC, Norris HJ: Glassy cell carcinoma of the cervix. Obstet Gynecol 60: 219, 1982

 

87

Costa MJ, Kenny MB, Hewan-Lowe K, Judd R: Glassy cell features in adenosquamous carcinoma of the uterine cervix. Am J Clin Pathol 96: 520, 1991

 

88

Ferry JA, Scully RE: “Adenoid cystic” carcinoma and adenoid basal carcinoma of the uterine cervix. A study of 28 cases. Am J Surg Pathol 12: 134, 1988

 

89

Lawrence JB, Mazur MT: Adenoid cystic carcinoma: A comparative pathologic study of tumors in salivary gland, breast, lung and cervix. Hum Pathol 13: 916, 1982

 

90

Prempree T, Villasanta U, Tang CK: Management of adenoid cystic carcinoma of the uterine cervix (cylindroma). Cancer 46: 1631, 1980

 

91

Dixit S, Singhal S, Vyas R et al: Adenoid cystic carcinoma of the cervix. J Postgrad Med 39: 211, 1993

 

92

Brainard JA, Hart WR: Adenoid basal epitheliomas of the uterine cervix. Am J Surg Pathol 22: 965, 1998

 

93

Jones MW, Kounelis S, Papadaki H, Bakker AN, Swalsky PA, Finkelstein SD: The origin and molecular characterization of adenoid basal carcinoma of the uterine cervix. Int J Gynecol Pathol 16: 301, 1997

 

94

Grayson W, Taylor LF, Cooper K: Adenoid basal carcinoma of the uterine cervix: detection of integrated human papillomavirus in a rare tumor of putative “reserve cell” origin. Int J Gynecol Pathol 16: 307, 1997

 

95

Pazdur R, Bonomi P, Slayton R et al: Neuroendocrine carcinoma of the cervix: Implications for staging and therapy. Gynecol Oncol 12: 120, 1981

 

96

Stassart J, Crum CP, Yordan EL et al: Argyrophilic carcinoma of the cervix: A report of a case with coexisting cervical intraepithelial neoplasia. Gynceol Oncol 13: 247, 1982

 

97

Wang KL, Yang YC, Wang TY et al: Neuroendocrine carcinoma of the uterine cervix: A clinicopathologic retrospectivestudy of 31 cases with prognostic implications. J Chemother. 2006 Apr;18(2):209-16.

 PubMed

98

Grayson W, Taylor LF, Cooper K: Carcinosarcoma of the uterine cervix: a report of eight cases withimmunohistochemical analysis and evaluation of human papillomavirus status. Am J Surg Pathol. 2001 Mar;25(3):338-47.

 PubMed

99

Clement PB: Miscellaneous primary tumors and metastatic tumors of the uterine cervix. Semin Diag Pathol 7: 228, 1990

 

100

Sevin B, Lu Y, Bloch DA, Nadji M, Koechli OR, Averette HE: Surgically defined prognostic parameters in patients with early cervical carcinoma. Cancer 78: 1438, 1996

 

101

Kamura T, Tsukamoto N, Tsuruchi N et al: Multivariate analysis of the histopathologic prognostic factors of cervical cancer patients undergoing radical hysterectomy. Cancer 69: 181, 1992

 

102

Fuller AF, Elliott N, Kosloff C et al: Determinants of increased risk for recurrence in patients undergoing radical hysterectomy for stage IB and IIA carcinoma of the cervix. Gynecol Oncol 33: 34, 1989

 

103

Barillot I, Horiot JC, Pigneux J et al: Carcinoma of the intact uterine cervix treated with radiotherapy alone: A French cooperative study: update and multivariate analysis of prognostic factors. Int J Radiat Oncol Biol Physics 38: 969, 1997

 

104

Shingleton HM, Gore H, Bradley DH et al: Adenocarcinoma of the cervix. I. Clinical evaluation and pathologic features. Am J Obstet Gynecol 139: 799, 1981

 

105

Yazigi R, Sandstad J, Munoz AK et al: Adenosquamous carcinoma of the cervix: Prognosis in stage IB. Obstet Gynecol 75: 1012, 1990

 

106

Gallup DG, Harper RH, Stock RJ: Poor prognosis in patients with adenosquamous cell carcinoma of the cervix. Obstet Gynecol 65: 416, 1985

 

107

Pak HY, Yokota SB, Paladugu RR et al: Glassy cell carcinoma of the cervix. Cancer 52: 307, 1983

 

108

Delgado G, Bundy BN, Fowler WC et al: A prospective surgical pathological study of stage I squamous carcinoma of the cervix: A Gynecologic Oncologic Group study. Gynecol Oncol 35: 314, 1989

 

109

Kishi Y, Hashimoto Y, Sakamoto Y et al: Thickness of uninvolved fibromuscular stroma and extrauterine spread of carcinoma of the uterine cervix. Cancer 60: 2331, 1987

 

110

Burghardt E, Pickel H: Local spread and lymph node involvement in cervical cancer. Obstet Gyencol 52: 138, 1978

 

111

Boyce JG, Fruchter RG, Nicastri AD et al: Vascular invasion in stage I carcinoma of the cervix. Cancer 53: 1175, 1984

 

112

White CK, Morley GW, Kumar NB: The prognostic significance of tumor emboli in lymphatic or vascular spaces of the cervical stroma in stage IB squamous cell carcinoma of the cervix. Am J Obstet Gynecol 149: 342, 1984

 

113

Baltzer J, Lohe KJ, Kopcke W et al: Histological criteria for the prognosis in patients with operated squamous cell carcinoma of the cervix. Gynecol Oncol 13: 184, 1982

 

114

Crissman JD, Budhraja M, Aron BS et al: Histopatholgic prognostic factors in stage II and III squamous cell carcinoma of the uterine cervix. Int J Gynecol Pathol 6: 97, 1987

 

115

Rettenmaier MA, Casanova DM, Micha JP et al: Radical hysterectomy and tailored postoperative radiation therapy in the management of bulky stage IB cervical cancer. Cancer 63: 2220, 1989

 

116

Giaroli A, Sananes C, Sardi JE et al: Lymph node metastases in carcinoma of the cervix uteri: Response to neoadjuvant chemotherapy and its impact on survival. Gynecol Oncol 39: 34, 1990

 

117

Pilleron JP, Durand JC, Hamelin JP: Prognostic value of node metastasis in cancer of the uterine cervix. Am J Obstet Gynecol 119: 458, 1974

 

118

Matsuyama T, Inoue I, Tsukamoto N et al: Stage Ib, IIa, and IIb cervix cancer, postsurgical staging, and prognosis. Cancer 54: 3072, 1984

 

119

Timmer PR, Aalders JG, Bouma J: Radical surgery after preoperative intracavitary radiotherapy for stage IB and IIA carcinoma of the uterine cervix. Gynecol Oncol 18: 206, 1984

 

120

Lifshitz S, Buchsbaum HJ: The spread of cervical carcinoma. In Sciarra JJ (ed): Gynecology and Obstetrics, vol 4, chap 6. Philadelphia, Harper and Row, 1980.

 

121

Berman ML, Bergen S, Salazar H: Influence of histological features and treatment on the prognosis of patients with cervical cancer metastatic to pelvic lymph nodes. Gynecol Oncol 39: 127, 1990

 

122

Brandt E, Lifshitz S: Scalene node biopsy in advanced carcinoma of the cervix uteri. Cancer 47: 1920, 1981

 

123

Lagasse LD, Creasman WT, Shingleton HM et al: Results and complications of operative staging in cervical cancer: Experience of the Gynecologic Oncology Group. Gynecol Oncol 9: 90, 1980

 

124

Rubin SC, Brookland R, Mikuta JJ et al: Para-aortic nodal metastases in early cervical carcinoma: Long-term survival following extended-field radiotherapy. Gynecol Oncol 18: 213, 1984

 

125

Vasilev SA, Schlaerth JB: Scalene lymph node sampling in cervical carcinoma: A reappraisal. Gynecol Oncol 37: 120, 1990

 

126

Krebs H, Helmkamp BF, Sevin B et al: Recurrent cancer of the cervix following radical hysterectomy and pelvic node dissection. Obstet Gynecol 59: 422, 1982

 

127

Larson DM, Copeland LJ, Stringer CA et al: Recurrent cervical carcinoma after radical hysterectomy. Gynecol Oncol 30: 381, 1988

 

128

Look KY, Rocereto TF: Relapse patterns in FIGO stage IB carcinoma of the cervix. Gynecol Oncol 38: 114, 1990

 

129

Bachaud JM, Mazabrey D, Berrebi A et al: Cutaneous metastatic lymphangitis from squamous cell carcinoma of the cervix. Dermatologica 180: 163, 1990

 

130

Katz HJ, Davies JNP: Death from cervix uteri carcinoma: the changing pattern. Gynecol Oncol 9: 86, 1980

 

131

Flint A, McCoy JP, Schade WJ et al: Cervical carcinoma antigen: distribution in neoplastic lesions of the uterine cervix and comparison to other tumor markers. Gynecol Oncol 30: 63, 1988

 

132

van Nagell JR, Donaldson ES, Wood EG et al: Carcinoembryonic antigen in carcinoma of the uterine cervix. Cancer 44: 944, 1979

 

133

Lindgrin J, Wahlstrom T, Seppala M: Tissue CEA in premalignant epithelial lesions and epidermoid carcinoma of the uterine cervix: Prognostic significance. Int J Cancer 23: 448, 1979

 

134

Borras G, Molina R, Xercavins J, Ballesta A, Iglesias J: Tumor antigens CA 19.9, CA 125, and CEA in carcinoma of the uterine cervix. Gynecol Oncol 57: 205, 1995

 

135

Kato H, Torigoe T: Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma. Cancer 40: 1621, 1977

 

136

Crombach G, Scharl A, Vierbuchen M et al: Detection of squamous cell carcinoma antigen in normal squamous epithelia and in squamous cell carcinomas of the uterine cervix. Cancer 63: 1337, 1989

 

137

Ngan HYS, Chan SYW, Wong LC et al: Serum squamous cell carcinoma antigen in the monitoring of radiotherapy treatment response in carcinoma of the cervix. Gynecol Oncol 37: 260, 1990

 

138

Crook T, Greenfield I, Howard J et al: Alterations in growth properties of human papilloma virus type 16 immortalised human cervical keratinocyte cell line correlate with amplification and overexpression of c-myc oncogene. Oncogene 5: 619, 1990

 

139

Sagae S, Kuzumaki N, Hisada T et al: Ras oncogene expression and prognosis of invasive squamous cell carcinomas of the uterine cervix. Cancer 63: 1577, 1989

 

140

Agnantis NJ, Spandidos DA, Mahera H et al: Immunohistochemical study of ras oncogene expression in endometrial and cervical human lesions. Eur J Gynaecol Oncol 9: 380, 1988

 

141

Riou G, Barrois M, Le MG et al: C-myc proto-oncogene expression and prognosis in early carcinoma of the uterine cervix. Lancet 4: 761, 1987

 

142

Mandai M, Konishi I, Komatsu T et al: Altered expression of nm 23-HI protein and c-erbB-2 proteins have prognostic significance in adenocarcinoma but not in squamous cell carcinoma of the uterine cervix. Cancer 75: 2523, 1995

 

143

Hunter RE, Longcope C, Keough P: Steroid hormone receptors in carcinoma of the cervix. Cancer 60: 392, 1987

 

144

Henry RJW, Goodman JDS, Godley M et al: Immunohistochemical study of cytoplasmic oestradiol receptor in normal, dysplastic and malignant cervical tissue. Br J Obstet Gynaecol 95: 927, 1988

 

145

Strang P: Cytogenetic and cytometric analyses in squamous cell carcinoma of the uterine cervix. Int J Gynecol Pathol 8: 54, 1989

 

146

Strang P, Eklund G, Stendahl U et al: S-phase rate as a predictor of early recurrences in carcinoma of the uterine cervix. Anticancer Res 7: 807, 1987

 

147

Connor JP, Miller DS, Bauer KD, Murad TM, Rademaker AW, Lurain JR: Flow cytometric evaluation of early invasive cervical cancer. Obstet Gynecol 81: 367, 1993

 

148

Kristensen GB, Kaern J, Abeler VM, Hagmar B, Trope CG, Pettersen EO: No prognostic impact of flow-cytometric measured DNA ploidy and S-phase fraction in cancer of the uterine cervix: a prospective study of 465 patients. Gynecol Oncol 57: 79, 1995

 
Back to Top